<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-174-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL 1% I.V INJ OR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Emulsion for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        102.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FRESENIUS KABI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 521]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Faisal Musaed El Seif Saudi Pharmaceutical Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Propofol Fresenius belongs to a group of medicines called &lsquo;general anaesthetics&rsquo;. General anaesthetics are<br />used to cause unconsciousness (sleep) so that surgical operations or other procedures can be performed.<br />They can also be used to sedate you (so that you are sleepy but not completely asleep).<br />Propofol Fresenius will be given to you as an injection by a doctor.<br />In adults and children over 1 month of age it is used to:<br />Help put you to sleep before an operation or other procedure.<br />Keep you asleep during an operation or other procedure.<br />Sedate you during diagnostic and surgical procedures, alone or in combination with local or regional<br />anaesthesia.<br />In people over 16 years of age it is also used to:<br />Sedate you when receiving artificial respiration in an Intensive Care Unit (ICU).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Propofol Fresenius<br />- if you are allergic to propofol or any of the other ingredients of this medicine (listed in section 6).<br />- if you are allergic to soya or peanut (see &ldquo;Propofol Fresenius contains soya-bean oil and sodium&rdquo; at<br />the end of section 2).<br />in patients of 16 years of age or younger for sedation in intensive care.<br />- If you are pregnant (see the section called &lsquo;Pregnancy and breast-feeding&rsquo;).<br />If any of the above apply to you, do not have Propofol Fresenius and tell your doctor, anaesthetist or<br />nurse. If you are not sure, talk to one of these people before having Propofol Fresenius.</p><p>Warnings and precautions<br />The use of Propofol fresenius is not recommended in newborn infants.<br />Talk to your doctor, anaesthetist or nurse before using Propofol fresenius.<br />Before you have this medicine, tell your doctor, anaesthetist or nurse<br />If you have ever had a fit or convulsion.<br />If you have ever been told that you have very high levels of fat in your blood.<br />If you have ever been told that your body has problems using fat.<br />If your body has lost lots of water (you are dehydrated).<br />If you have any other health problems, such as problems with your heart, breathing, kidneys or liver.<br />If you have been generally unwell for some time.<br />If you have mitochondrial disease.<br />If you are not sure if any of the above apply to you, talk to your doctor or nurse before having Propofol<br />fresenius.<br />Other medicines and Propofol fresenius<br />Tell your doctor if you are taking or have recently taken or might take any other medicines.<br />This includes medicines that you buy without a prescription and herbal medicines.<br />In particular, tell your doctor, anaesthetist or nurse if you are taking any of the following medicines:<br />Rifampicin (for tuberculosis - TB)<br />Pregnancy, breast-feeding and fertility<br />Do not have Propofol Fresenius if you are pregnant.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your<br />doctor or pharmacist for advice before taking this medicine.<br />Driving and using machines<br />After having Propofol you may still feel sleepy for some time. Do not drive or use any tools or machines<br />until you are sure the effects have worn off.<br />If you are able to go home shortly after receiving Propofol, do not drive a car or use any tools or<br />machines.<br />Ask your doctor when you can start doing these activities again and when you can go back to work.<br />Propofol Fresenius contains soya-bean oil and sodium<br />Propofol Fresenius contains soya-bean oil. This can rarely cause severe allergic reactions (see &ldquo;Do not use<br />Propofol Fresenius&rdquo;). Tell your doctor if you know that you have allergic reactions to soya-bean oil or<br />peanut.<br />This medicinal product contains less than 1 mmol (23 mg) sodium per 100 ml, i.e. essentially &acute;sodiumfree`<br />.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will be given Propofol Fresenius by a doctor. It will be given to you as an injection into a vein.<br />This is usually in the back of your hand or in your forearm.<br />The doctor will give you the injection using a needle or through a fine plastic tube called a &lsquo;cannula&rsquo;.<br />The doctor can also use an electric pump to control how fast the injection is given. This may be done<br />if you are having a long operation or if you are in an Intensive Care Unit.<br />Page 3 of 8<br />The dose of Propofol Fresenius varies from one patient to another. The amount of Propofol Fresenius<br />that you need depends on your age, size, physical fitness and the level of sleepiness or sleep that you<br />need. The doctor will give you the correct dose to start and to sustain anaesthesia or to achieve the<br />required level of sedation, by carefully watching your responses and vital signs (pulse, blood pressure,<br />breathing etc.).<br />You may need several different medicines to keep you asleep or sleepy, free from pain, breathing in a<br />healthy way and to keep your blood pressure steady. The doctor will decide which medicines you need<br />and when you need them.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Side effects that can happen during anaesthesia<br />The following side effects can happen during anaesthesia (while the injection is being given to you or<br />when you are sleepy or asleep). Your doctor will be looking out for these. If they happen, your doctor will<br />give you appropriate treatment.</p><p>Very common (may affect more than 1 in 10 people)<br />A feeling of pain at the site of the injection (while the injection is being given, before you fall asleep).<br />Common (may affect up to 1 in 10 people)<br />Slow heartbeat<br />Low blood pressure<br />Changes in your breathing pattern<br />Rare (may affect up to 1 in 1,000 people)<br />Twitching and shaking of your body, or fits (may also happen when you wake up).<br />Unusual colour of urine (may also happen when you wake up).<br />Very rare (may affect up to 1 in 10, 000 people)<br />Allergic reaction<br />Build up of fluid in the lungs which can make you very breathless (may also happen when you wake<br />up)<br />Stopping of your heart beat.<br />Not known (frequency cannot be estimated from the available data)<br />Shallow breathing<br />Side effects that can happen after anaesthesia<br />The following side effects can happen after anaesthesia (when you are waking up or after you have woken<br />up).<br />Common (may affect up to 1 in 10 people)<br />Headache<br />Feeling sick (nausea), being sick (vomiting).<br />Uncommon (may affect up to 1 in 100 people)<br />Swelling and redness along a vein or blood clots.</p><p>Very rare (may affect up to 1 in 10,000 people)<br />Being unconscious after the operation (when this has happened, the patients have recovered without<br />problems)<br />High temperature (Fever )<br />Feeling sexually aroused.<br />Redness or soreness where the injection was given<br />Tissue damage.<br />Not known (frequency cannot be estimated from the available data)<br />A feeling of pain at the site of the injection.<br />Swelling at the site of injection.<br />Other possible side effects<br />The following side effects have been seen when Propofol Fresenius is used in intensive care at higher<br />doses than recommended.<br />Very rare (may affect up to1 in 10,000 people)<br />Heart failure.<br />Inflamed pancreas (pancreatitis) which causes severe stomach pain.<br />Too much acid in your blood. This may make you breathe more quickly.<br />Increased amount of potassium in your blood.<br />High blood level of a type of fat called lipids.<br />Abnormal heart beat.<br />Enlargement of the liver.<br />Kidney failure.<br />The following side effects have been seen in children in intensive care when Propofol Fresenius has<br />been stopped suddenly.<br />Common (may affect up to 1 in 10 people)<br />&lsquo;Withdrawal symptoms&rsquo;. These include unusual behaviour, sweating, shaking and feeling anxious.<br />Flushing of the skin.<br />Do not be concerned by this list of possible side effects. You may not get any of them.<br />Not known: frequency cannot be estimated from the available data<br />Euphoric mood.<br />Involuntary movements.<br />Drug abuse and dependence on Propofol Fresenius, mostly by healthcare professionals.<br />Abnormal ECG.<br />Breakdown of muscle cells (rhabdomyolysis).<br />If you think you have a side effect or if you notice any side effects not listed in this leaflet, please tell<br />your doctor or nurse.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects<br />not listed in this leaflet.</p><p>Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-<br />2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the ampoule/vial and the outer packaging<br />after EXP. The expiry date refers to the last day of that month.<br />Do not store above 25 &deg;C.<br />Do not freeze.<br />After opening the product must be used immediately.<br />Administration systems with undiluted Propofol Fresenius should be replaced 12 hours after opening of<br />the ampoule or vial. Dilutions with 5 % w/v glucose or 0.9 % w/v sodium chloride intravenous infusion<br />solution or an admixture with 1 % preservative-free lidocaine injection solution (at least 2 mg propofol per<br />ml) should be prepared aseptically (controlled and validated conditions preserved) immediately before<br />administration and has to be administered within 6 hours after preparation.<br />Containers should be shaken before use.<br />Do not use this medicine if you notice two layers after shaking the emulsion.<br />Use only homogeneous preparations and undamaged containers.<br />For single use only. Any unused emulsion must be discarded.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw<br />away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is propofol.<br />1 ml emulsion contains 10 mg propofol.<br />Each 20 ml ampoule contains 200 mg propofol.<br />Each 50 ml vial contains 500 mg propofol.<br />Each 100 ml vial contains 1000 mg propofol.<br />- The other ingredients are refined soya-bean oil, purified egg phosphatides, glycerol, oleic acid,<br />sodium hydroxide, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Propofol Fresenius is a white oil-in-water emulsion for injection or infusion.
Propofol Fresenius is available in colourless glass ampoules or glass vials. The glass vials are sealed with
rubber stoppers.
Pack sizes:
Packs containing 5 glass ampoules with 20 ml emulsion
Packs containing 10 glass ampoules with 20 ml emulsion
Packs containing 1 glass vial with 50 or 100 ml emulsion
Packs containing 10 glass vials with 50 or 100 ml emulsion
Packs containing 15 glass vials with 50 or 100 ml emulsion
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:</p><p>Fresenius Kabi Deutschland GmbH</p><p>Manufacturer:<br />Fresenius Kabi Austria GmbH<br />Hafnerstra&szlig;e 36<br />A-8055 Graz<br />Austria<br />Fresenius Kabi AB<br />Rapsgatan 7<br />S-75174 Uppsala<br />Sweden</p><p>This medicinal product is authorised in the Member States of the EEA under the following names:<br /><br />Belgium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propofol Fresenius 1 %<br />Germany&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propofol 1% (10mg/1 ml) Fresenius, Emulsion zur Injektion oder Infusion<br />France&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propofol Fresenius 10 mg/ml, emulsion injectable ou pour perfusion<br />Ireland&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fresenius Propofol 1 %<br />Portugal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propofol 1 % Fresenius<br />Spain&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Propofol Fresenius 10 mg/ml emulsi&oacute;n para inyecci&oacute;n o perfusi&oacute;n<br />Sweden &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Propofol Fresenius Kabi 10 mg/ml<br />United Kingdom Fresenius Propofol 1 %</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2017.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt">ﯾﻨﺘﻤﻲ ﻋﻘﺎر<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ﻟﻤﺠﻤﻮﻋﺔ ﻣﻦ اﻷدوﯾﺔ ﯾُﻄﻠﻖ ﻋﻠﯿﮭﺎ اﻷدوﯾﺔ &quot;اﻟﻤﺨﺪرة اﻟﻌﺎﻣﺔ.&quot; ﺗﺴﺘﺨﺪم اﻷدوﯾﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.75pt">اﻟﻤﺨﺪرة اﻟﻌﺎﻣﺔ ﻹﻓﻘﺎد اﻟﻤﺮﯾﺾ اﻟﻮﻋﻲ )ﺟﻌﻠﮫ ﯾﻨﺎم( ﺣﺘﻰ ﯾﻤﻜﻦ اﻟﻘﯿﺎم ﺑﺎﻟﻌﻤﻠﯿﺎت اﻟﺠﺮاﺣﯿﺔ أو اﻹﺟﺮاءات اﻷﺧﺮى.</p><p dir="RTL" style="margin-right:23pt">ﻛﻤﺎ ﯾﻤﻜﻦ اﺳﺘﺨﺪاﻣﮭﺎ أﯾﻀﺎ ﻓﻰ ﺟﻌﻞ اﻟﻤﺮﯾﺾ ﻓﻰ ﺣﺎﻟﺔ ﻣﻦ اﻟﺨﺪر )ﺣﺘﻰ ﯾﺒﺪو ﻧﺎﺋﻤﺎً ، وﻟﻜﻦ ﻟﯿﺲ ﻧﺎﺋﻤﺎً ﺗﻤﺎﻣﺎ.(</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt">ﺳﻮف ﯾﻘﻮم طﺒﯿﺐ ﺑﺈﻋﻄﺎءك ﻋﻘﺎر<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ﻋﻠﻰ ھﯿﺌﺔ ﺣﻘﻦ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.65pt">ﯾﺴﺘﺨﺪم<strong> ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل</strong> ﻟﻠﺒﺎﻟﻐﯿﻦ واﻷطﻔﺎل اﻟﺬﯾﻦ ﺗﺰﯾﺪ أﻋﻤﺎرھﻢ ﻋﻦ ﺷﮭﺮ ﻓﯿﻤﺎ ﯾﻠﻰ:</p><p dir="RTL" style="margin-left:142.85pt">&middot; &nbsp;&nbsp;ﻣﺴﺎﻋﺪﺗﻚ ﻋﻠﻰ اﻟﻨﻮم ﻗﺒﻞ اﻟﻌﻤﻠﯿﺎت اﻟﺠﺮاﺣﯿﺔ أو اﻹﺟﺮاءات اﻷﺧﺮى.</p><p dir="RTL" style="margin-left:148.6pt; margin-right:0cm">&middot; &nbsp;&nbsp;اﻹﺑﻘﺎء ﻋﻠﯿﻚ ﻧﺎﺋﻤﺎ أﺛﻨﺎء اﻟﻌﻤﻠﯿﺎت اﻟﺠﺮاﺣﯿﺔ أو اﻹﺟﺮاءات اﻷﺧﺮى.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:350.2pt; margin-right:0cm">إﻧﺎﻣﺘﻚ أﺛﻨﺎء اﻹﺟﺮاءات اﻟﺘﺸﺨﯿﺼﯿﺔ والعمليات اﻟﺠﺮاحية، ﺳﻮاء ﺑﻤﻔﺮده أو ﻣﻊ اﻷدوﯾﺔ اﻟﻤﺨﺪرة اﻟﻤﻮﺿﻌﯿﺔ.</p><p dir="RTL" style="margin-left:199.25pt; margin-right:0cm">وﯾﺴﺘﺨﺪم<strong> ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل</strong> ﻟﻤﻦ ﺗﺰﯾﺪ أﻋﻤﺎرھﻢ ﻋﻦ 16 ﺳﻨﺔ ﻓﻰ:</p><p dir="RTL" style="margin-left:11.1pt; margin-right:0cm">&middot; &nbsp;&nbsp;&nbsp;إﻧﺎﻣﺔ اﻟﻤﺮﺿﻰ اﻟﻜﺒﺎر ﻣﻤﻦ ﺗﺰﯾﺪ اﻋﻤﺎرھﻢ ﻋﻦ 16 ﺳﻨﺔ اﻟﺬﯾﻦ ﯾﺘﻠﻘﻮن اﻟﺘﻨﻔﺲ اﻻﺻﻄﻨﺎﻋﻲ ﻓﻲ وﺣﺪات</p><p dir="RTL" style="margin-left:332.1pt; margin-right:0cm">اﻟﻌﻨﺎﯾﺔ اﻟﻤﺮﻛﺰة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:179.0pt; margin-right:0cm; text-align:right"><strong>ﯾﺠﺐ ﻋﺪم اﺳﺘﻌﻤﺎل ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس ﻓﻰ اﻟﺤﺎﻻت اﻟﺘﺎﻟﯿﺔ</strong><strong>:</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:11.1pt; margin-right:2.6pt; text-align:right">إذا ﻛﺎن ﻟﺪﯾﻚ ﺣﺴﺎﺳﯿﺔ ﻣﻦ ﺑﺮوﺑﻮﻓﻮل ، أو ﻣﻦ أى ﻣﻦ ﻣﻜﻮﻧﺎت ھﺬا اﻟﻌﻘﺎر )اﻟﻤﺪرﺟﺔ ﻓﻰ اﻟﻘﺴﻢ .(6 - &nbsp;&nbsp;&nbsp;إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﻓﺮط اﻟﺤﺴﺎﺳﯿﺔ ﻟﻠﺼﻮﯾﺎ أو اﻟﻔﻮل اﻟﺴﻮداﻧﻲ )أﻧﻈﺮ&quot;ﻣﻜﻮﻧﺎت ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس &quot;</p><p dir="RTL" style="margin-left:11.0pt; margin-right:0cm; text-align:right">ﺣﯿﺚ ﯾﺤﺘﻮى ﻋﻠﻰ زﯾﺖ ﻓﻮل اﻟﺼﻮﯾﺎ واﻟﺼﻮدﯾﻮم -&nbsp;&nbsp; ﻓﻰ ﻧﮭﺎﯾﺔ اﻟﻘﺴﻢ رﻗﻢ (2 ، وذﻟﻚ ﺑﺎﻟﻨﺴﺒﺔ ﻹﻧﺎﻣﺔ</p><p dir="RTL" style="margin-left:128.35pt; margin-right:0cm; text-align:right">اﻟﻤﺮﺿﻰ اﻟﺒﺎﻟﻐﯿﻦ ﻣﻦ اﻟﻌﻤﺮ 16 ﺳﻨﺔ أو أﻗﻞ ﻓﻲ وﺣﺪات اﻟﻌﻨﺎﯾﺔ اﻟﻤﺮﻛﺰة:</p><p dir="RTL" style="margin-left:176.7pt; text-align:right">- &nbsp;&nbsp;&nbsp;إذا ﻛﻨﺖ ﺣﺎﻣﻞ )اﻧﻈﺮ ﻗﺴﻢ &quot; اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ.(&quot;</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:2.6pt; margin-right:0cm; text-align:right">إذا اﻧﻄﺒﻘﺖ ﻋﻠﯿﻚ أﯾﺎ ﻣﻦ اﻷﻣﻮر اﻟﻮاردة أﻋﻼه ، ﻻ ﺗﺄﺧﺬ<strong> ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> واﺑﻠﻎ طﺒﯿﺒﻚ أو طﺒﯿﺐ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">اﻟﺘﺨﺪﯾﺮ أو اﻟﻤﻤﺮﺿﺔ. وإن ﻟﻢ ﺗﻜﻦ ﻣﺘﺄﻛﺪا ﺗﺤﺪث اﻟﻰ أى ﻣﻨﮭﻢ ﻗﺒﻞ أﺧﺬ ھﺬا اﻟﻌﻘﺎر.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﺗﺤﺬﯾــــــــﺮات واﺣﺘﯿﺎطـــــــــــــــــــــﺎت</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.65pt; text-align:right">ﻻ ﯾﻮﺻﻰ ﺑﺈﺳﺘﺨﺪام<strong> ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ﻟﻠﺮﺿﻊ ﺣﺪﯾﺜﻰ اﻟﻮﻻدة</p><p dir="RTL" style="margin-right:22.7pt; text-align:right">ﺗﺤﺪث اﻟﻰ طﺒﯿﺒﻚ اﻟﻤﻌﺎﻟﺞ &nbsp;أو طﺒﯿﺐ اﻟﺘﺨﺪﯾﺮ أو اﻟﻤﻤﺮﺿﺔ ﻗﺒﻞ اﻟﺒﺪء ﻓﻰ اﺳﺘﻌﻤﺎل ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل ﻓﯿﺮﺳﯿﻨﯿﺎس.</p><p dir="RTL" style="margin-right:22.7pt; text-align:right">وﻗﺒﻞ أﺧﺬ ھﺬا اﻟﻌﻘﺎر ، ﻋﻠﯿﻚ اﺑﻼغ طﺒﯿﺒﻚ اﻟﻤﻌﺎﻟﺞ&nbsp; أو طﺒﯿﺐ اﻟﺘﺨﺪﯾﺮ أو اﻟﻤﻤﺮﺿﺔ إذا:</p><p dir="RTL" style="margin-left:2.6pt; margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;ﻛﻨﺖ ﻗﺪ أﺻﺒﺖ ﻓﻰ أي وﻗﺖ ﻣﻀﻰ ﺑﺘﺸﻨﺠﺎت أو ﻧﻮﺑﺎت ﻋﺮﺿﯿﺔ.</p><p dir="RTL" style="margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;ﺳﺒﻖ أن ﺗﻢ اﺑﻼﻏﻚ أن ﻣﺴﺘﻮﯾﺎت اﻟﺪھﻮن ﻓﻰ اﻟﺪم ﻟﺪﯾﻚ ﻣﺮﺗﻔﻌﺔ ﺟﺪا.</p><p dir="RTL" style="margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;ﺳﺒﻖ أن ﺗﻢ اﺑﻼﻏﻚ أن ﻟﺪﯾﻚ ﻣﺸﺎﻛﻞ ﻓﻰ اﻟﺠﺴﻢ ﻣﻦ اﺳﺘﺨﺪام اﻟﺪھﻮن.</p><p dir="RTL" style="margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;ﻛﺎن ﺟﺴﻤﻚ ﻗﺪ ﻓﻘﺪ ﻛﻤﯿﺎت ﻣﻦ اﻟﻤﺎء )ﺗﻌﺎﻧﻰ ﻣﻦ اﻟﺠﻔﺎف.(</p><p dir="RTL" style="margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;ﻛﺎن ﻟﺪﯾﻚ أى ﻣﺸﺎﻛﻞ ﺻﺤﯿﺔ أﺧﺮى أى ﻣﺸﺎﻛﻞ ﻓﻰ اﻟﻘﻠﺐ أو اﻟﺘﻨﻔﺲ أو اﻟﻜﻠﻰ أو اﻟﻜﺒﺪ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;ﻛﻨﺖ ﺑﺼﻔﺔ ﻋﺎﻣﺔ ﻣﻌﺘﻞ اﻟﺼﺤﺔ أو ﻣﺘﻮﻋﻚ ﻟﺒﻌﺾ اﻟﻮﻗﺖ.</p><p dir="RTL" style="margin-right:40.75pt; text-align:right">&sect; &nbsp;&nbsp;إذا ﻛﻨﺖ ﻣﺼﺎب ﺑﻤﺮض ﻣُﺘَﻘَ&nbsp; ﱢﺪرِي.</p><p dir="RTL" style="margin-right:22.7pt; text-align:right">إن ﻟﻢ ﺗﻜﻦ ﻣﺘﺄﻛﺪا ﻣﻤﺎ إذا ﻛﺎن ﻣﺎورد اﻋﻼه ﯾﻨﻄﺒﻖ ﻋﻠﯿﻚ ﻣﻦ ﻋﺪﻣﺔ ، ﯾﺮﺟﻰ اﻟﺘﺤﺪث اﻟﻰ طﺒﯿﺒﻚ اﻟﻤﻌﺎﻟﺞ &nbsp;أو طﺒﯿﺐ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt; text-align:right">اﻟﺘﺨﺪﯾﺮ أو اﻟﻤﻤﺮﺿﺔ ﻗﺒﻞ اﻟﺒﺪء ﻓﻰ اﺳﺘﻌﻤﺎل ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل ﻓﯿﺮﺳﯿﻨﯿﺎس</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>اﻷدوﯾﺔ اﻷﺧﺮى و ﻋﻘﺎر ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</p><p dir="RTL" style="margin-left:2.6pt; margin-right:25.7pt; text-align:right">ﯾﺠﺐ إﺑﻼغ اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻰ ، إذا ﻛﻨﺖ ﺗﺘﻌﺎطﻰ أو ﻣﻦ اﻟﻤﺘﻮﻗﻊ أن ﺗﺘﻌﺎطﻰ أﯾﺔ أدوﯾﺔ أﺧﺮى. وﯾﺸﻤﻞ ذﻟﻚ</p><p dir="RTL" style="margin-right:22.95pt; text-align:right">اﻷدوﯾﺔ اﻟﺘﻰ ﺗﺸﺘﺮﯾﮭﺎ ﺑﺪون وﺻﻔﺔ طﺒﯿﺔ وﻛﺬﻟﻚ اﻷﻋﺸﺎب اﻟﻄﺒﯿﺔ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt; text-align:right">وﯾﺠﺐ اﺑﻼغ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ&nbsp; أو طﺒﯿﺐ اﻟﺘﺨﺪﯾﺮ أو اﻟﻤﻤﺮﺿﺔ إذا ﻛﻨﺖ ﺗﺄﺧﺬ أﯾﺎ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﺎﻟﯿﺔ:</p><p dir="RTL" style="margin-left:288.9pt; margin-right:0cm; text-align:right">&middot; &nbsp;&nbsp;رﯾﻔﺎﻣﺒﯿﺴﯿﻦ )ﻟﻤﺮض اﻟﺴﻞ.(</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>اﻟﺤﻤــــــﻞ واﻟﺮﺿــــــــــــــﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ واﻟﺨﺼﻮﺑـــــــــﺔ</p><p dir="RTL" style="margin-left:11.1pt; margin-right:22.7pt; text-align:right">ﻻ ﺗﺄﺧﺬ<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> إذا ﻛﻨﺖ ﺣﺎﻣﻼ. إذا ﻛﻨﺖ ﺣﺎﻣﻼ أو ﻣﺮﺿﻌﺎ ، أو ﺗﻌﺘﻘﺪﯾﻦ اﻧﻚ ﻗﺪ ﺗﻜﻮﻧﯿﻦ ﺣﺎﻣﻼ ، أو ﺗﻨﻮﯾﻦ اﻟﺤﻤﻞ ، ﯾﺠﺐ اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt; text-align:right">ﻗﺒﻞ اﻟﺒﺪء ﻓﻰ أﺧﺬ ھﺬا اﻟﺪواء.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>اﻟﻘﯿــــــــــــــــــﺎدة واﺳﺘﺨﺪام اﻵﻻت</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt; text-align:right">ﻗﺪ ﯾﺴﺘﻤﺮ اﻟﺸﻌﻮر ﺑﺎﻟﻨﻌﺎس ﺑﻌﺪ ﺗﻨﺎول ﺑﺮوﺑﻮﻓﻮل ﻟﺒﻌﺾ اﻟﻮﻗﺖ. ﻟﺬا ﯾﺠﺐ ﻋﺪم اﻟﻘﯿﺎدة أو إﺳﺘﺨﺪام أي أدوات أو آﻻت</p><p dir="RTL" style="margin-left:11.1pt; margin-right:22.7pt; text-align:right">ﺣﺘﻰ ﺗﺘﺄﻛﺪ ﻣﻦ أن آﺛﺎر ھﺬا اﻟﻌﻘﺎر ﻗﺪ زاﻟﺖ ﺗﻤﺎﻣﺎ. إذا اﺻﺒﺤﺖ ﻗﺎدرا ﻋﻠﻰ اﻟﻌﻮدة إﻟﻰ اﻟﻤﻨﺰل ﺑﻌﺪ وﻗﺖ ﻗﺼﯿﺮ ﻣﻦ أﺧﺬ ﺑﺮوﺑﻮﻓﻮل، ﯾﺠﺐ ﻋﺪم ﻗﯿﺎدة اﻟﺴﯿﺎرة أو اﻟﻌﻮدة</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.75pt; text-align:right">إﻟﻰ اﻟﻤﻨﺰل دون ﻣﺮاﻓﻖ..</p><p dir="RTL" style="margin-right:22.75pt; text-align:right">اﺳﺄل طﺒﯿﺒﻚ ﻣﺘﻰ ﯾﻤﻜﻨﻚ ﻣﺰاوﻟﺔ ھﺬه اﻷﻧﺸﻄﺔ ﻣﺠﺪدا وﻣﺘﻰ ﯾﻤﻜﻨﻚ اﻟﻌﻮدة ﻟﻠﻌﻤﻞ.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:11.1pt; margin-right:22.65pt; text-align:right"><strong>ﯾﺤﺘﻮى ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس ﻋﻠﻰ زﯾﺖ ﻓﻮل اﻟﺼﻮﯾﺎ واﻟﺼﻮدﯾﻮم</strong><strong>.</strong><strong> </strong>ﯾﺤﺘﻮى<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ﻋﻠﻰ زﯾﺖ ﻓﻮل اﻟﺼﻮﯾﺎ ، ﻣﻤﺎ ﻗﺪ ﯾﺆدي ﻓﻲ ﺣﺎﻻت ﻧﺎدرة إﻟﻰ ﺣﺪوث ﻓﺮط اﻟﺤﺴﺎﺳﯿﺔ )اﻧﻈﺮ ﻣﻮاﻧﻊ اﻹﺳﺘﺨﺪام ﻓﻰ اﻟﻘﺴﻢ رﻗﻢ .(2 وﯾﺠﺐ اﺑﻼغ اﻟﻄﺒﯿﺐ إذا ﻛﻨﺖ ﻋﻠﻰ ﻋﻠﻢ ﺑﺄن ﻟﺪﯾﻚ ﺣﺴﺎﺳﯿﺔ ﻣﻦ زﯾﺖ ﻓﻮل</p><p dir="RTL" style="margin-left:14.0pt; margin-right:22.65pt; text-align:right">اﻟﺼﻮﯾﺎ أو اﻟﻔﻮل اﻟﺴﻮداﻧﻰ. ﯾﺤﺘﻮي ھﺬا اﻟﻤﺴﺘﺤﻀﺮ اﻟﻄﺒﻰ ﻋﻠﻰ أﻗﻞ ﻣﻦ 1 ﻣﻠﻠﻲ ﻣﻮل ) 23ﻣﻠﺠﻢ( ﻣﻦ اﻟﺼﻮدﯾﻮم ﻓﻰ ﻛﻞ 100 ﻣﻠﻠﻲ ﻟﺘﺮ، أي أﻧﮫ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.65pt; text-align:right">ﺑﺎﻷﺳﺎس ﺧﺎل ﻣﻦ اﻟﺼﻮدﯾﻮم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">ﺳﻮف ﯾﻘﻮم طﺒﯿﺐ ﺑﺈﻋﻄﺎءك ﻋﻘﺎر<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ، وﺳﻮف ﺗﻌﻄﻰ ﻟﻚ ﻋﻠﻰ ھﯿﺌﺔ ﺣﻘﻦ ﻓﻲ اﻟﻮرﯾﺪ. وﻋﺎدة ﻣﺎ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">ﯾﺘﻢ اﻟﺤﻘﻦ ﻓﻲ اﻟﺠﺰء اﻟﺨﻠﻔﻲ ﻣﻦ ﯾﺪك أو ﻓﻲ اﻟﺴﺎﻋﺪ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">ﺳﻮف ﯾﻌﻄﯿﻚ اﻟﻄﺒﯿﺐ اﻟﺤﻘﻦ ﺑﺎﺳﺘﺨﺪام إﺑﺮة أو ﻣﻦ ﺧﻼل أﻧﺒﻮب ﺑﻼﺳﺘﯿﻜﻲ ﺟﯿﺪ ﯾﺴﻤﻰ &quot;ﻗﻨﯿﺔ - ﻛﺎﻧﯿﻮﻻ.&quot;</p><p dir="RTL" style="margin-right:2.6pt; text-align:right">&nbsp;ﯾﺴﺘﻄﯿﻊ اﻟﻄﺒﯿﺐ أﯾﻀﺎ اﺳﺘﺨﺪام ﻣﻀﺨﺔ ﻛﮭﺮﺑﺎﺋﯿﺔ ﻟﻠﺘﺤﻜﻢ ﻓﻲ ﻣﺪى ﺳﺮﻋﺔ إﻋﻄﺎء اﻟﺤﻘﻦ ﺣﯿﺚ ﯾﺘﻢ ذﻟﻚ إذا ﻛﻨﺖ</p><p dir="RTL" style="margin-right:2.6pt; text-align:right">ﺧﺎﺿﻊ ﻟﻌﻤﻠﯿﺔ ﺟﺮاﺣﯿﺔ طﻮﯾﻠﺔ أو إذا ﻛﻨﺖ ﻓﻲ وﺣﺪة اﻟﻌﻨﺎﯾﺔ اﻟﻤﺮﻛﺰة.</p><p dir="RTL" style="margin-left:11.1pt; margin-right:0cm; text-align:right">ﺗﺨﺘﻠﻒ ﺟﺮﻋﺔ<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> &nbsp;اﻟﻼزﻣﺔ ﻣﻦ ﻣﺮﯾﺾ ﻵﺧﺮ، وﺗﺘﻮﻗﻒ اﻟﺠﺮﻋﺔ اﻟﺘﻲ ﺗﻌﻄﻰ ﻟﻚ ﻋﻠﻰ ﺳﻨﻚ ،</p><p dir="RTL" style="margin-left:14.0pt; margin-right:0cm; text-align:right">ووزن ﺟﺴﻤﻚ، وﺣﺎﻟﺘﻚ اﻟﺒﺪﻧﯿﺔ وﻣﺴﺘﻮى اﻹﻧﺎﻣﺔ اﻟﻤﻄﻠﻮب. و ﺳﻮف ﯾﻌﻄﻲ اﻟﻄﺒﯿﺐ اﻟﺠﺮﻋﺔ اﻟﺴﻠﯿﻤﺔ ﻟﻠﺒﺪاﯾﺔ واﻻﺑﻘﺎء</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">ﻋﻠﻰ اﻟﺘﺨﺪﯾﺮ أو ﺗﺤﻘﯿﻖ اﻟﻤﺴﺘﻮى اﻟﻤﻄﻠﻮب ﻣﻦ اﻟﺘﺨﺪﯾﺮ وذﻟﻚ ﻋﻦ طﺮﯾﻖ اﻟﻤﺮاﻗﺒﺔ اﻟﺤﺬرة ﻻﺳﺘﺠﺎﺑﺎﺗﻚ واﻟﻌﻼﻣﺎت</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">اﻟﺤﯿﻮﯾﺔ ﻟﺪﯾﻚ ) اﻟﻨﺒﺾ وﺿﻐﻂ اﻟﺪم واﻟﺘﻨﻔﺲ ... إﻟﺦ.(</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">ﻗﺪ ﯾﺤﺘﺎج اﻷﻣﺮ إﻟﻰ ﻋﺪة أدوﯾﺔ ﻣﺨﺘﻠﻔﺔ ﻟﻠﺤﻔﺎظ ﻋﻠﻰ اﻟﻤﺮﯾﺾ ﻧﺎﺋﻤﺎ أو ﻧﺎﻋﺴﺎ ، ﻻﯾﺸﻌﺮ ﺑﺄﻟﻢ، وﯾﺘﻨﻔﺲ ﺑﻄﺮﯾﻘﺔ ﺻﺤﯿﺔ، ﻣﻊ اﻟﺤﻔﺎظ ﻋﻠﻰ ﺿﻐﻂ دﻣﺔ ﺛﺎﺑﺘﺎ. وﺳﻮف ﯾﻘﺮر اﻟﻄﺒﯿﺐ اﻷدوﯾﺔ اﻟﺘﻲ ﯾﺤﺘﺎج اﻟﻤﺮﯾﺾ إﻟﯿﮭﺎ ، وﻣﺘﻰ ﯾﺤﺘﺎج</p><p dir="RTL" style="margin-left:2.6pt; margin-right:2.6pt; text-align:right">إﻟﯿﮭﺎ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:56.55pt; margin-right:0cm; text-align:right">ﻣﺜﻞ ﺟﻤﯿﻊ اﻷدوﯾﺔ ، ﻗﺪ ﯾﺆدى ھﺬا اﻟﺪواء اﻟﻰ ﺣﺪوث آﺛﺎر ﺟﺎﻧﺒﯿﺔ ، ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ ﻋﺪم ﺣﺪوﺛﮭﺎ ﻟﺪى اﻟﺠﻤﯿﻊ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻰ ﯾﻤﻜﻦ أن ﺗﺤﺪث أﺛﻨﺎء اﻟﺘﺨﺪﯾﺮ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">ﯾﻤﻜﻦ أن ﺗﺤﺪث اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ أﺛﻨﺎء اﻟﺘﺨﺪﯾﺮ )أﺛﻨﺎء اﻟﺤﻘﻦ أو أﺛﻨﺎء اﻟﻨﻌﺴﺎن أو اﻟﻨﻮم.( ﺳﻮف ﯾﺘﺎﺑﻊ طﺒﯿﺒﻚ ھﺬه</p><p dir="RTL" style="margin-left:231.05pt; text-align:right">اﻵﺛﺎر. و ﺳﻮف ﯾﻌﻄﯿﻚ طﺒﯿﺒﻚ اﻟﻌﻼج اﻟﻤﻨﺎﺳﺐ إذا ﺣﺪﺛﺖ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﺷﺎﺋﻌﺔ ﺟﺪا: ﻗﺪ ﺗﺼﯿﺐ أﻛﺜﺮ ﻣﻦ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10 ﻣﺮﺿﻰ.</p><p dir="RTL" style="margin-left:150.55pt; margin-right:0cm; text-align:right">&sect; &nbsp;&nbsp;اﻟﺸﻌﻮر ﺑﺎﻷﻟﻢ ﻓﻰ ﻣﻮﺿﻊ اﻟﺤﻘﻦ )أﺛﻨﺎء اﻟﺤﻘﻦ أو ﻗﺒﻞ أن ﺗﻐﻂ ﻓﻰ اﻟﻨﻮم.(</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﺷـــﺎﺋﻌﺔ: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10 ﻣﺮﺿﻰ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﺑﻂء ﺿﺮﺑﺎت اﻟﻘﻠﺐ.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;اﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;ﺗﻐﯿﺮات ﻓﻲ ﻧﻤﻂ اﻟﺘﻨﻔﺲ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﻧــــــــــﺎدرة: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 1000 ﻣﺮﯾﺾ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;اﻟﻮﺧﺰ ورﻋﺸﺔ اﻟﺠﺴﻢ، أو ﺗﺸﻨﺠﺎت )ﻗﺪ ﺗﺤﺪث أﯾﻀﺎ ﻋﻨﺪ اﻻﺳﺘﯿﻘﺎظ.(</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;ﺗﻐﯿﺮ ﻏﯿﺮ ﻣﻌﺘﺎد ﻓﻰ ﻟﻮن اﻟﺒﻮل )ﻗﺪ ﺗﺤﺪث أﯾﻀﺎ ﻋﻨﺪ اﻻﺳﺘﯿﻘﺎظ.(</p><p>&nbsp;</p><p>ﻧــــــــــﺎدرة ﺟﺪا: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10000 ﻣﺮﯾﺾ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;رد ﻓﻌﻞ ﺗﺤﺴﺴﻲ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;ﺗﺠﻤﻊ ﺳﻮاﺋﻞ ﻓﻲ اﻟﺮﺋﺘﯿﻦ ﻣﻤﺎ ﯾﺠﻌﻞ اﻟﻤﺮﯾﺾ ﯾﻘﻄﻊ اﻟﻨﻔﺲ )ﻗﺪ ﯾﺤﺪث أﯾﻀﺎ ﻋﻨﺪ اﻻﺳﺘﯿﻘﺎظ(</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect;&nbsp;&nbsp;&nbsp; ﺗﻮﻗﻒ ﺿﺮﺑﺎت اﻟﻘﻠﺐ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﻏﯿﺮ ﻣﻌﺮوﻓﺔ: ﻻ ﯾﻤﻜﻦ ﺗﻘﺪﯾﺮ ﺗﻜﺮار ﺗﻠﻚ اﻵﺛﺎر ﻣﻦ واﻗﻊ اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﺎﺣﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﺿﯿﻖ ﺗﻨﻔﺲ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻰ ﯾﻤﻜﻦ أن ﺗﺤﺪث ﺑﻌﺪ اﻟﺘﺨﺪﯾﺮ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">ﯾﻤﻜﻦ أن ﺗﺤﺪث اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ ﺑﻌﺪ اﻟﺘﺨﺪﯾﺮ )ﻋﻨﺪ اﻹﺳﺘﯿﻘﺎظ أو ﺑﻌﺪ اﻹﺳﺘﯿﻘﺎظ.(</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﺷﺎﺋﻌﺔ: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10 ﻣﺮﺿﻰ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.7pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;اﻟﺼﺪاع.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.7pt; text-align:right">&sect; &nbsp;&nbsp;اﻟﺸﻌﻮر ﺑﺎﻟﻐﺜﯿﺎن أو اﻟﻐﺜﯿﺎن )اﻟﻘﯿﺊ.(</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﻏﯿﺮ ﺷﺎﺋﻌﺔ: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 100 ﻣﺮﺿﻰ.</p><p dir="RTL" style="margin-left:235.75pt; margin-right:0cm; text-align:right">&sect; &nbsp;&nbsp;ﺗﻮرم واﺣﻤﺮار ﺣﻮل اﻟﻮرﯾﺪ أو ﺗﺠﻤﻌﺎت دﻣﻮﯾﺔ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﻧــــــــــﺎدرة ﺟﺪا: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10000 ﻣﺮﯾﺾ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;ﻓﻘﺪان اﻟﻮﻋﻲ ﺑﻌﺪ اﻟﻌﻤﻠﯿﺔ )ﻋﻨﺪ ﺣﺪوث ذﻟﻚ، ﯾﺴﺘﻌﯿﺪ اﻟﻤﺮﯾﺾ وﻋﯿﮫ دون ﻣﺸﺎﻛﻞ(</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ارﺗﻔﺎع درﺟﺔ اﻟﺤﺮارة )ﺣﻤﻰ(</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;اﻹﺳﺘﺜﺎرة اﻟﺠﻨﺴﯿﺔ.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;اﺣﻤﺮار أو وﺟﻊ ﻓﻰ ﻣﻜﺎن إﻋﻄﺎء اﻟﺤﻘﻦ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﺗﻠﻒ اﻷﻧﺴﺠﺔ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﻏﯿﺮ ﻣﻌﺮوﻓﺔ: ﻻ ﯾﻤﻜﻦ ﺗﻘﺪﯾﺮ ﺗﻜﺮار ﺗﻠﻚ اﻵﺛﺎر ﻣﻦ واﻗﻊ اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﺎﺣﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.7pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;اﻟﺸﻌﻮر ﺑﺄﻟﻢ ﻓﻰ ﻣﻜﺎن إﻋﻄﺎء اﻟﺤﻘﻦ<strong>.</strong></p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.7pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ورم ﻓﻰ ﻣﻜﺎن إﻋﻄﺎء اﻟﺤﻘﻦ<strong>.</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ اﻷﺧﺮى</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.6pt; text-align:right">ﺗﻼﺣﻆ ﺣﺪوث اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ ﻋﻨﺪ اﺳﺘﺨﺪام<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ﺑﺠﺮﻋﺎت أﻋﻠﻰ ﻣﻦ اﻟﻤﻮﺻﻰ ﺑﮭﺎ ﻓﻰ اﻟﻌﻨﺎﯾﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.7pt; text-align:right">اﻟﻤﺮﻛﺰة.</p><p>ﻧــــــــــﺎدرة ﺟﺪا: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10000 ﻣﺮﯾﺾ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﻓﺸﻞ اﻟﻘﻠﺐ.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;اﻟﺘﮭﺎب اﻟﺒﻨﻜﺮﯾﺎس اﻟﺬي ﯾﺴﺒﺐ أﻟﻢ ﺷﺪﯾﺪ ﻓﻲ اﻟﺒﻄﻦ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;زﯾﺎدة اﻟﺤﻤﺾ أﻛﺜﺮ ﻣﻦ اﻟﻼزم ﻓﻲ اﻟﺪم. ﻣﻤﺎ ﻗﺪ ﯾﺠﻌﻠﻚ ﺗﺘﻨﻔﺲ ﺑﺴﺮﻋﺔ أﻛﺒﺮ.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;زﯾﺎدة ﻛﻤﯿﺔ اﻟﺒﻮﺗﺎﺳﯿﻮم ﻓﻲ اﻟﺪم.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;ارﺗﻔﺎع ﻣﺴﺘﻮى اﻟﺪھﻮن ﻓﻰ اﻟﺪم.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﻋﺪم اﻧﺘﻈﺎم ﺿﺮﺑﺎت اﻟﻘﻠﺐ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﺗﻀﺨﻢ اﻟﻜﺒﺪ.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﻓﺸﻞ ﻛﻠﻮي.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:18.55pt; margin-right:0cm; text-align:right">ﻛﻤﺎ ﺗﻼﺣﻆ ﺣﺪوث اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ ﻟﺪى اﻷطﻔﺎل ﻓﻲ اﻟﻌﻨﺎﯾﺔ اﻟﻤﺮﻛﺰة ﻋﻨﺪ إﯾﻘﺎف<strong> ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس</strong> ﻓﺠﺄة.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﺷـــﺎﺋﻌﺔ: ﻗﺪ ﺗﺼﯿﺐ 1 ﻣﻦ ﺑﯿﻦ ﻛﻞ 10 ﻣﺮﺿﻰ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&quot;أﻋﺮاض اﻹﻧﺴﺤﺎب&quot; وﺗﺸﻤﻞ اﻟﺴﻠﻮﻛﯿﺎت ﻏﯿﺮ اﻟﻌﺎدﯾﺔ، واﻟﺘﻌﺮق، واﻟﺮﻋﺸﺔ واﻟﺸﻌﻮر ﺑﺎﻟﻘﻠﻖ.</p><p dir="RTL" style="margin-right:51.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;اﺣﻤﺮار اﻟﺠﻠﺪ.</p><p dir="RTL" style="margin-left:138.65pt; text-align:right">ﻻ ﺗﺸﻌﺮ ﺑﺎﻟﻘﻠﻖ ﻣﻦ ھﺬه اﻟﻘﺎﺋﻤﺔ ﺑﺎﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ. ﻗﺪ ﻻ ﺗﺼﺎب ﺑﺄي ﻣﻨﮭﺎ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>ﻏﯿﺮ ﻣﻌﺮوﻓﺔ: ﻻ ﯾﻤﻜﻦ ﺗﻘﺪﯾﺮ ﺗﻜﺮار ﺗﻠﻚ اﻵﺛﺎر ﻣﻦ واﻗﻊ اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﺎﺣﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.7pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;اﻟﺸﻌﻮر ﺑﺎﻟﺒﮭﺠﺔ وﺗﺤﺴﻦ اﻟﻤﺰاج.</p><p dir="RTL" style="margin-right:23.7pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﺣﺮﻛﺎت ﻻ ارادﯾﺔ.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:11.1pt; margin-right:0cm; text-align:right"><strong>ﻓﺮﯾﺰﻧﯿﻮس</strong> ، وﻣﻌﻈﻤﮭﻢ ﻣﻦ ﻗﺒﻞ اﻟﻤﺘﺨﺼﺼﯿﻦ ﻓﻲ اﻟﺮﻋﺎﯾﺔ</p><p>&nbsp;</p><p dir="RTL" style="margin-left:3.0pt; margin-right:0cm; text-align:right">ﻋﻠﻰ<strong> ﺑﺮوﺑﻮﻓﻮل</strong></p><p>&nbsp;</p><p dir="RTL" style="margin-left:3.0pt; margin-right:0cm; text-align:right">&sect; &nbsp;&nbsp;&nbsp;ﺗﻌﺎطﻲ&nbsp; اﻟﻤﺨﺪرات&nbsp; واﻹدﻣﺎن</p><p dir="RTL" style="margin-left:77.4pt; text-align:right">اﻟﺼﺤﯿﺔ.</p><p dir="RTL" style="margin-left:22.05pt; text-align:right">&sect; &nbsp;&nbsp;&nbsp;رﺳﻢ اﻟﻘﻠﺐ ﻏﯿﺮ طﺒﯿﻌﻲ.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:251.95pt; text-align:right">&sect; &nbsp;&nbsp;اﻧﮭﯿﺎر اﻟﺨﻼﯾﺎ اﻟﻌﻀﻠﯿﺔ )اﻧﺤﻼل اﻟﺮﺑﯿﺪات.(</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p>إذا ﮐﻨﺖ ﺗﻌﺘﻘﺪ أن ﻟﺪﯾﻚ آﺛﺎر ﺟﺎﻧﺒﯿﺔ أو إذا ﻻﺣﻈﺖ أي آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻏﯿﺮ ﻣﺪرﺟﺔ ﻓﻲ ھﺬه اﻟﻨﺸﺮة، ﯾﺮﺟﯽ إﺑﻼغ اﻟﻄﺒﯿﺐ أو</p><p dir="RTL" style="margin-left:259.15pt; margin-right:5.55pt; text-align:right; text-indent:146.5pt"><strong>اﻟﻤﻤﺮﺿﺔ</strong><strong>.</strong><strong> </strong><strong>اﻹﺑـــــــــــــﻼغ ﻋﻦ اﻵﺛـــــــــــﺎر اﻟﺠﺎﻧﺒﯿـــــــــــــﺔ</strong></p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">إذا ظﮭﺮت ﻟﺪﯾﻚ أﯾﺔ آﺛﺎر ﺟﺎﻧﺒﯿﺔ ، ﺗﺤﺪث اﻟﻰ طﺒﯿﺒﻚ اﻟﻤﻌﺎﻟﺞ أو اﻟﺼﯿﺪﻟﻰ أو اﻟﻤﻤﺮﺿﺔ ، وﯾﺸﻤﻞ ذﻟﻚ أﯾﺔ آﺛﺎر ﺟﺎﻧﺒﯿﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">ﻣﺤﺘﻤﻠﺔ ﻏﯿﺮ اﻟﻤﺪرﺟﺔ ﻓﻰ ھﺬة اﻟﻨﺸﺮة.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.75pt; text-align:right"><strong>اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right"><!--[if gte vml 1]><o:wrapblock><v:group
  id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
  margin-left:84.35pt;margin-top:12.1pt;width:426.6pt;height:101.9pt;z-index:-15728128;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1687,242" coordsize="8532,2038">
  <v:shape id="_x0000_s1027" style='position:absolute;left:1687;top:241;
   width:8532;height:2038' coordorigin="1687,242" coordsize="8532,2038" path="m10219,242r-9,l10210,251r,2019l1697,2270r,-2019l10210,251r,-9l1697,242r-10,l1687,251r,2019l1687,2280r10,l10210,2280r9,l10219,2270r,-2019l10219,242xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
   left:7120;top:253;width:2948;height:266' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1028' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=right dir=RTL style='text-align:left;line-height:
      13.3pt;mso-line-height-rule:exactly;direction:rtl;unicode-bidi:embed'><span
      lang=AR-SA style='font-size:12.0pt'>اﻟﻤﺮﻛﺰ اﻟﻮطﻨﻲ ﻟﻠﺘﯿﻘﻆ واﻟﺴﻼﻣﺔ اﻟﺪواﺋﯿﺔ</span><span
      dir=LTR style='font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
   left:1804;top:548;width:7545;height:1716' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1029' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=right style='margin-right:.9pt;text-align:right;
      line-height:13.3pt;mso-line-height-rule:exactly'><span style='font-size:
      12.0pt'>+966 11 205 7662 :<span style='letter-spacing:-.9pt'> </span><span
      lang=AR-SA dir=RTL>ﻓﺎﻛﺲ</span><o:p></o:p></span></p>
      <p class=MsoNormal dir=RTL style='margin-top:.85pt;margin-right:.9pt;
      margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:right;
      direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:12.0pt'>اﺗﺼﻞ<span
      style='letter-spacing:1.55pt'> </span>ﺑﺎﻟﻤﺮﻛﺰ<span style='letter-spacing:
      1.6pt'> </span>اﻟﻮطﻨﻲ<span style='letter-spacing:-.05pt'> </span>ﻟﻠﺘﯿﻘﻆ<span
      style='letter-spacing:1.6pt'> </span>واﻟﺴﻼﻣﺔ<span style='letter-spacing:
      -.05pt'> </span>اﻟﺪواﺋﯿﺔ<span style='letter-spacing:1.6pt'> </span>ﻋﻠﻰ<span
      style='letter-spacing:1.5pt'> </span>ھﺎﺗﻒ<span style='letter-spacing:
      1.65pt'> </span>رﻗﻢ</span><span dir=LTR></span><span dir=LTR></span><span
      dir=LTR style='font-size:12.0pt'><span dir=LTR></span><span dir=LTR></span>:</span><span
      dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;
      letter-spacing:1.7pt'><span dir=RTL></span><span dir=RTL></span> </span><span
      dir=LTR></span><span dir=LTR></span><span dir=LTR style='font-size:12.0pt'><span
      dir=LTR></span><span dir=LTR></span>8222</span><span dir=RTL></span><span
      dir=RTL></span><span style='font-size:12.0pt;letter-spacing:1.55pt'><span
      dir=RTL></span><span dir=RTL></span> </span><span dir=LTR></span><span
      dir=LTR></span><span dir=LTR style='font-size:12.0pt'><span dir=LTR></span><span
      dir=LTR></span>203</span><span dir=RTL></span><span dir=RTL></span><span
      style='font-size:12.0pt;letter-spacing:1.6pt'><span dir=RTL></span><span
      dir=RTL></span> </span><span dir=LTR></span><span dir=LTR></span><span
      dir=LTR style='font-size:12.0pt'><span dir=LTR></span><span dir=LTR></span>11</span><span
      dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;
      letter-spacing:1.55pt'><span dir=RTL></span><span dir=RTL></span> </span><span
      dir=LTR></span><span dir=LTR></span><span dir=LTR style='font-size:12.0pt'><span
      dir=LTR></span><span dir=LTR></span>+966</span><span dir=RTL></span><span
      dir=RTL></span><span style='font-size:12.0pt;letter-spacing:1.5pt'><span
      dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
      style='font-size:12.0pt'>ﺗﺤﻮﯾﻠﺔ</span><span dir=LTR></span><span dir=LTR></span><span
      dir=LTR style='font-size:12.0pt'><span dir=LTR></span><span dir=LTR></span>:<o:p></o:p></span></p>
      <p class=MsoNormal align=right style='margin-right:.9pt;text-align:right'><span
      style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>2340 – 2334 – 2354 –
      2353 – 2356 –<span style='letter-spacing:-.25pt'> </span>2317<o:p></o:p></span></p>
      <p class=MsoNormal dir=RTL style='margin-top:.95pt;margin-right:.9pt;
      margin-bottom:0cm;margin-left:188.6pt;margin-bottom:.0001pt;text-align:
      right;text-indent:71.25pt;line-height:105%;direction:rtl;unicode-bidi:
      embed'><span lang=AR-SA style='font-size:12.0pt;line-height:105%'>اﻟﺮﻗﻢ<span
      style='letter-spacing:-.55pt'> </span>اﻟﻤﺠﺎﻧﻰ</span><span dir=LTR></span><span
      dir=LTR></span><i style='mso-bidi-font-style:normal'><span dir=LTR
      style='font-size:12.0pt;line-height:105%'><span dir=LTR></span><span
      dir=LTR></span>:</span></i><span dir=RTL></span><span dir=RTL></span><span
      style='font-size:12.0pt;line-height:105%;letter-spacing:-.5pt'><span
      dir=RTL></span><span dir=RTL></span> </span><span dir=LTR></span><span
      dir=LTR></span><span dir=LTR style='font-size:12.0pt;line-height:105%'><span
      dir=LTR></span><span dir=LTR></span>8002490000</span><span dir=RTL></span><span
      dir=RTL></span><span lang=AR-SA style='font-size:12.0pt;line-height:105%'><span
      dir=RTL></span><span dir=RTL></span> اﻟﺒﺮﯾﺪ<span style='letter-spacing:
      -.6pt'> </span>اﻹﻟﻜﺘﺮوﻧﻰ</span><span dir=LTR></span><span dir=LTR></span><span
      dir=LTR style='font-size:12.0pt;line-height:105%'><span dir=LTR></span><span
      dir=LTR></span>:</span><span dir=LTR><a href="mailto:npc.drug@sfda.gov.sa"><span
      dir=RTL></span><span dir=RTL></span><span dir=RTL style='font-size:12.0pt;
      line-height:105%;color:windowtext;letter-spacing:-.6pt;text-decoration:
      none;text-underline:none'><span dir=RTL></span><span dir=RTL></span> </span><span
      style='font-size:12.0pt;line-height:105%;color:windowtext'>npc.drug@sfda.gov.sa</span></a></span><span
      dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;
      line-height:105%;letter-spacing:-.05pt'><span dir=RTL></span><span
      dir=RTL></span> </span><span lang=AR-SA style='font-size:12.0pt;
      line-height:105%'>اﻟﻤﻮﻗﻊ<span style='letter-spacing:-1.3pt'> </span>ﻋﻠﻰ
      اﻹﻧﺘﺮﻧﺖ</span><span dir=LTR></span><span dir=LTR></span><span dir=LTR
      style='font-size:12.0pt;line-height:105%'><span dir=LTR></span><span
      dir=LTR></span>:</span><span dir=LTR><a href="http://www.sfda.gov.sa/npc"><span
      dir=RTL></span><span dir=RTL></span><span dir=RTL style='font-size:12.0pt;
      line-height:105%;color:windowtext;text-decoration:none;text-underline:
      none'><span dir=RTL></span><span dir=RTL></span> </span><span
      style='font-size:12.0pt;line-height:105%;color:windowtext'>www.sfda.gov.sa/npc</span></a></span><span
      dir=LTR style='font-size:12.0pt;line-height:105%'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
   left:9578;top:521;width:131;height:587' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1030' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:14.65pt;mso-line-height-rule:exactly'><span
      style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol'>·<o:p></o:p></span></p>
      <p class=MsoNormal style='line-height:14.65pt;mso-line-height-rule:exactly'><span
      style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol'>·<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1031" type="#_x0000_t202" style='position:absolute;
   left:9578;top:1385;width:131;height:880' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1031' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:14.65pt;mso-line-height-rule:exactly'><span
      style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol'>·<o:p></o:p></span></p>
      <p class=MsoNormal style='line-height:14.65pt;mso-line-height-rule:exactly'><span
      style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol'>·<o:p></o:p></span></p>
      <p class=MsoNormal style='line-height:14.65pt;mso-line-height-rule:exactly'><span
      style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol'>·<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="RTL">اﻟﻤﺮﻛﺰ اﻟﻮطﻨﻲ ﻟﻠﺘﯿﻘﻆ واﻟﺴﻼﻣﺔ اﻟﺪواﺋﯿﺔ</p><p style="margin-right:0.9pt">ﻓﺎﻛﺲ: +966 11 205 7662</p><p dir="RTL" style="margin-left:0cm; margin-right:0.9pt">اﺗﺼﻞ ﺑﺎﻟﻤﺮﻛﺰ اﻟﻮطﻨﻲ ﻟﻠﺘﯿﻘﻆ واﻟﺴﻼﻣﺔ اﻟﺪواﺋﯿﺔ ﻋﻠﻰ ھﺎﺗﻒ رﻗﻢ: 8222 203 11 +966 ﺗﺤﻮﯾﻠﺔ:</p><p dir="RTL" style="margin-left:188.6pt; margin-right:0.9pt; text-indent:71.25pt">2340 &ndash; 2334 &ndash; 2354 &ndash; 2353 &ndash; 2356 &ndash; 2317</p><p dir="RTL" style="margin-left:188.6pt; margin-right:0.9pt; text-indent:71.25pt">اﻟﺮﻗﻢ اﻟﻤﺠﺎﻧﻰ<em>:</em> 8002490000</p><p dir="RTL" style="margin-left:188.6pt; margin-right:0.9pt; text-indent:71.25pt">اﻟﺒﺮﯾﺪ اﻹﻟﻜﺘﺮوﻧﻰ: npc.drug@sfda.gov.sa اﻟﻤﻮﻗﻊ ﻋﻠﻰ اﻹﻧﺘﺮﻧﺖ: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:11.1pt; margin-right:5.6pt; text-align:right">اﺣﻔﻆ ھﺬا اﻟﺪواء ﺑﻌﯿﺪا ﻋﻦ ﻧﻈﺮ وﻋﻦ ﻣﺘﻨﺎول أﯾﺪى اﻷطﻔﺎل. ﻻ ﺗﺴﺘﻌﻤﻞ ھﺬا اﻟﺪواء ﺑﻌﺪ &quot;ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ&quot; اﻟﻤﺪون ﻋﻠﻰ ﻣﻠﺼﻖ اﻷﻣﺒﻮل وﻋﻠﻰ اﻟﻌﻠﺒﺔ اﻟﻜﺮﺗﻮن. ﯾﺸﯿﺮ ﺗﺎرﯾﺦ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ اﻟﻰ آﺧﺮ ﯾﻮم ﻓﻰ اﻟﺸﮭﺮ اﻟﻤﺬﻛﻮر.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">ﯾﺤﻔﻆ ﻓﻰ درﺟﺔ ﺣﺮارة أﻗﻞ ﻣﻦ 25 درﺟﺔ ﻣﺌﻮﯾﺔ.</p><p dir="RTL" style="margin-left:297.3pt; margin-right:5.55pt; text-align:right; text-indent:-51.15pt">ﯾﺠﺐ ﻋﺪم وﺿﻊ ھﺬا اﻟﺪواء ﻓﻰ اﻟﻔﺮﯾﺰر ﻟﺘﺠﻨﺐ ﺗﺠﻤﺪة. ﯾﺠﺐ اﺳﺘﺨﺪام ھﺬا اﻟﻤﺴﺘﺤﻀﺮ ﻓﻮر ﻓﺘﺤﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">ﯾﻨﺒﻐﻲ اﺳﺘﺒﺪال وﺗﻐﯿﯿﺮ أﻧﻈﻤﺔ إﻋﻄﺎء ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس ﻏﯿﺮ اﻟﻤﺨﻔﻒ ﺑﻌﺪ 12 ﺳﺎﻋﺔ ﻣﻦ ﻓﺘﺢ اﻷﻣﺒﻮل. و ﯾﺘﻢ ﺗﺨﻔﯿﻒ</p><p>&nbsp;</p><p dir="RTL" style="margin-left:11.1pt; margin-right:0cm; text-align:right">0,9 % وزن / ﺣﺠﻢ ﺑﻀﺦ ﻣﺤﻠﻮل ﻛﻠﻮرﯾﺪ</p><p>&nbsp;</p><p dir="RTL" style="margin-left:4.55pt; margin-right:0cm; text-align:right">أو ﺑﺎﺳﺘﺨﺪام</p><p>&nbsp;</p><p dir="RTL" style="margin-left:4.65pt; margin-right:0cm; text-align:right">ھﺬا اﻟﻤﺴﺘﺤﻀﺮ ﺑﺎﺳﺘﺨﺪام 5 % وزن / ﺣﺠﻢ ﻣﻦ اﻟﺠﻠﻮﻛﻮز ،</p><p>&nbsp;</p><p dir="RTL" style="margin-left:14.35pt; margin-right:0cm; text-align:right">اﻟﺼﻮدﯾﻮم ﻋﻦ طﺮﯾﻖ اﻟﻮرﯾﺪ ، أو ﺑﻤﺰﺟﺔ ﻣﻊ&nbsp; 1 % ﻣﻦ ﻣﺤﻠﻮل ﻟﯿﺪوﺳﯿﻦ اﻟﺨﺎﻟﻲ ﻣﻦ اﻟﻤﻮاد اﻟﺤﺎﻓﻈﺔ اﻟﻤﺨﺼﺺ ﻟﻠﺤﻘﻦ</p><p dir="RTL" style="margin-left:256.75pt; margin-right:0cm; text-align:right">)ﻋﻠﻰ اﻷﻗﻞ 2 ﻣﻠﺠﻢ ﻣﻦ اﻟﺒﺮوﺑﻮﻓﻮل ﻟﻜﻞ ﻣﻠﻠﻲ ﻟﺘﺮ.(</p><p>&nbsp;</p><p dir="RTL" style="margin-left:16.0pt; margin-right:0cm; text-align:right">ﻣﻌﻘﻤﺔ )ظﺮوف ﺗﻌﻘﯿﻢ ﺻﺤﯿﺤﺔ وﺳﻠﯿﻤﺔ وﺧﺎﺿﻌﺔ ﻟﻠﺮﻗﺎﺑﺔ واﻟﺴﯿﻄﺮة( ﻓﻮرا ﻗﺒﻞ</p><p>&nbsp;</p><p dir="RTL" style="margin-left:3.0pt; margin-right:0cm; text-align:right">ﺑﺼﻮرة</p><p>&nbsp;</p><p dir="RTL" style="margin-left:3.0pt; margin-right:0cm; text-align:right">و ﯾﺠﺐ ﺗﺤﻀﯿﺮاﻟﻤﺤﻠﻮل</p><p>&nbsp;</p><p dir="RTL" style="margin-left:0cm; text-align:right">6 ﺳﺎﻋﺎت ﻣﻦ اﻟﺘﺤﻀﯿﺮ.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:5.7pt; text-align:right">اﻻﻋﻄﺎء ، وﯾﺠﺐ اﻋﻄﺎؤه ﺧﻼل ﻣﺎ ﻻﯾﺰﯾﺪ ﻋﻦ</p><p dir="RTL" style="margin-left:0cm; margin-right:5.6pt; text-align:right">ﯾﺠﺐ رج اﻟﻮﻋﺎء ﺟﯿﺪا ﻗﺒﻞ اﻻﺳﺘﺨﺪام.</p><p>&nbsp;</p><p dir="RTL" style="margin-right:5.75pt; text-align:right">إن ظﮭﺮت طﺒﻘﺘﯿﻦ ﺑﻌﺪ اﻟﺮج ، ﯾﺠﺐ ﻋﺪم اﺳﺘﺨﺪام اﻟﻤﺴﺘﺤﻠﺐ.</p><p dir="RTL" style="margin-right:5.7pt; text-align:right">اﺳﺘﺨﺪم ﻓﻘﻂ اﻟﻤﺴﺘﺤﻀﺮ اﻟﻤﺘﺠﺎﻧﺲ ، واﻷوﻋﯿﺔ ﻏﯿﺮ اﻟﺘﺎﻟﻔﺔ.</p><p dir="RTL" style="margin-left:14.2pt; margin-right:5.6pt; text-align:right">ﻋﻨﺪ اﻻﺳﺘﺨﺪام ﻟﻤﺮة واﺣﺪة : ﯾﺠﺐ اﻟﺘﺨﻠﺺ ﻣﻦ اﻟﻤﺴﺘﺤﻠﺐ ﻏﯿﺮ اﻟﻤﺴﺘﺨﺪم. ﯾﺠﺐ ﻋﺪم اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ ﻓﻲ ﻣﯿﺎه اﻟﺼﺮف أو اﻟﻨﻔﺎﯾﺎت اﻟﻤﻨﺰﻟﯿﺔ ، ﻛﻤﺎ ﯾﺠﺐ اﻹﺳﺘﻔﺴﺎر ﻣﻦ اﻟﺼﯿﺪﻻﻧﻲ ﻋﻦ طﺮﯾﻘﺔ</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.7pt; text-align:right">اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﻲ ﻟﻢ ﺗﻌﺪ ﻣﻄﻠﻮﺑﺔ ، ﺣﯿﺚ أن ﻣﺜﻞ ھﺬة اﻟﺘﺪاﺑﯿﺮ ﺗﺴﺎﻋﺪ ﻓﻰ ﺣﻤﺎﯾﺔ اﻟﺒﯿﺌﺔ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:286.85pt; margin-right:0cm; text-align:right"><strong>-</strong> &nbsp;&nbsp;&nbsp;اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ھﻰ ﺑﺮوﺑﻮﻓﻮل.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:58.7pt; text-align:right">ﯾﺤﺘﻮى ﻛﻞ ﻣﻠﯿﻠﺘﺮ ﻣﻦ اﻟﻤﺴﺘﺤﻠﺐ ﻋﻠﻰ 10 ﻣﻠﻠﻰ ﺟﺮام ﻣﻦ اﻟﺒﺮوﺑﻮﻓﻮل.</p><p dir="RTL" style="margin-right:58.65pt; text-align:right">ﻛﻞ أﻣﺒﻮل ﺳﻌﺔ 10 ﻣﻠﯿﻠﺘﺮ ﯾﺤﺘﻮى ﻋﻠﻰ 200 ﻣﻠﻠﻰ ﺟﺮام ﻣﻦ اﻟﺒﺮوﺑﻮﻓﻮل.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:58.65pt; text-align:right">ﻛﻞ أﻣﺒﻮل ﺳﻌﺔ 50 ﻣﻠﯿﻠﺘﺮ ﯾﺤﺘﻮى ﻋﻠﻰ 500 ﻣﻠﻠﻰ ﺟﺮام ﻣﻦ اﻟﺒﺮوﺑﻮﻓﻮل.</p><p dir="RTL" style="margin-right:58.65pt; text-align:right">ﻛﻞ أﻣﺒﻮل ﺳﻌﺔ 100 ﻣﻠﯿﻠﺘﺮ ﯾﺤﺘﻮى ﻋﻠﻰ 1000 ﻣﻠﻠﻰ ﺟﺮام ﻣﻦ اﻟﺒﺮوﺑﻮﻓﻮل.</p><p dir="RTL" style="margin-left:3.4pt; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:119.45pt; text-align:right">- &nbsp;&nbsp;اﻟﻤﻜﻮﻧﺎت&nbsp; اﻷﺧﺮى&nbsp; ﻋﺒﺎرة&nbsp; ﻋﻦ زيت فول الصويا المكرر،&nbsp;وھﻀﻤﯿﺪاتﻓﻮﺳﻔﺎت&nbsp;اﻟﺒﯿﺾ اﻟﻤﻨﻘﻰ ، واﻟﺠﻼﯾﻜﯿﺮول ، وﺣﻤﺾ اﻷوﻟﯿﻚ ، وھﯿﺪروﻛﺴﯿﺪ اﻟﺼﻮدﯾﻮم ، وﻣﺎء ﻟﻠﺤﻘﻦ.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:2.6pt; margin-right:5.65pt; text-align:right">ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس ﻋﺒﺎرة ﻋﻦ زﯾﺖ أﺑﯿﺾ ﻋﻠﻰ ھﯿﺌﺔ ﻣﺴﺘﺤﻠﺐ ﻣﺎﺋﻲ ﻟﻠﺤﻘﻦ أو اﻟﻀﺦ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.6pt; text-align:right">ﯾﺘﻮﻓﺮ ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس ﻓﻰ أﻣﺒﻮﻻت زﺟﺎﺟﯿﺔ ، ﻋﺪﯾﻤﺔ اﻟﻠﻮن. وھﺬة اﻷﻣﺒﻮﻻت اﻟﺰﺟﺎﺟﯿﺔ ﻣﻘﻔﻠﺔ ﺑﺴﺪادات ﻣﻄﺎطﯿﺔ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:5.7pt; text-align:right"><u>أﺣﺟﺎم اﻟﻌﺑوات</u><u>:</u></p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.65pt; text-align:right">&middot; &nbsp;&nbsp;ﻋﺒﻮات ﺗﺤﺘﻮى ﻋﻠﻰ 5 أﻣﺒﻮﻻت ﺑﻜﻞ ﻣﻨﮭﺎ 20 ﻣﻠﻠﻰ ﻟﺘﺮ ﻣﻦ اﻟﻤﺴﺘﺤﻠﺐ.</p><p dir="RTL" style="margin-left:2.6pt; margin-right:23.65pt; text-align:right">&middot; &nbsp;&nbsp;ﻋﺒﻮات ﺗﺤﺘﻮى ﻋﻠﻰ 1 أﻣﺒﻮل واﺣﺪ ﺑﮫ 50 أو 100 ﻣﻠﻠﻰ ﻟﺘﺮ ﻣﻦ اﻟﻤﺴﺘﺤﻠﺐ</p><p dir="RTL" style="margin-left:4.0pt; margin-right:0cm; text-align:right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot; &nbsp;&nbsp;ﻋﺒﻮات ﺗﺤﺘﻮى ﻋﻠﻰ 10 أﻣﺒﻮﻻت ﺑﻜﻞ ﻣﻨﮭﺎ 50 أو 100 ﻣﻠﻠﻰ ﻟﺘﺮ ﻣﻦ اﻟﻤﺴﺘﺤﻠﺐ</p><p dir="RTL" style="margin-left:0cm; margin-right:23.65pt; text-align:right">&middot; &nbsp;&nbsp;ﻋﺒﻮات ﺗﺤﺘﻮى ﻋﻠﻰ 15 أﻣﺒﻮل ﺑﻜﻞ ﻣﻨﮭﺎ 50 أو 100ﻣﻠﻠﻰ ﻟﺘﺮ ﻣﻦ اﻟﻤﺴﺘﺤﻠﺐ</p><p dir="RTL" style="margin-left:0cm; margin-right:23.65pt; text-align:right">&middot; &nbsp;&nbsp;ﯾﺠﻮز ﻋﺪم ﺗﺴﻮﯾﻖ ﺟﻤﯿﻊ اﻟﻌﺒﻮات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt; text-align:right"><strong>اﻟﺠﮭﺔ اﻟﺤﺎﺻﻠﺔ ﻋﻠﻰ اﻟﺘﺮﺧﯿﺺ ﺑﺎﻟﺘﺴﻮﯾﻖ</strong><strong>:</strong></p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.65pt; text-align:right">)ﺗﺬﻛﺮ وﺗﺪون ﻣﺤﻠﯿﺎ(</p><p>ﺟﮭﺔ اﻟﺼﻨﻊ:</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.7pt; text-align:right">ﺷﺮﻛﺔ ﻓﺮﯾﺰﻧﯿﻮس ﻛﺎﺑﻰ اﻟﻨﻤﺴﺎ &ndash; اﻟﻤﺤﺪودة</p><p dir="RTL" style="margin-left:365.0pt; margin-right:22.7pt; text-align:right; text-indent:-1.2pt">36 ﺷﺎرع ھﺎﻓﯿﻨﺮ اﯾﮫ8055- ﺟﺮاز</p><p dir="RTL" style="margin-left:2.6pt; margin-right:22.8pt; text-align:right">اﻟﻨﻤﺴﺎ</p><p>&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:22.7pt; text-align:right">ﺷﺮﻛﺔ ﻓﺮﯾﺰﻧﯿﻮس ﻛﺎﺑﻰ - اﯾﮫ ﺑﻰ</p><p dir="RTL" style="margin-left:13.15pt; margin-right:22.7pt; text-align:right; text-indent:36.6pt">7 راﺑﺴﺠﺎﺗﻦ اس - 75174 اوﺑﺴﺎﻻ</p><p dir="RTL" style="margin-left:0cm; margin-right:22.75pt; text-align:right">اﻟﺴﻮﯾﺪ</p><p>ھﺬا اﻟﻤﺴﺘﺤﻀﺮ اﻟﺪواﺋﻰ ﻣﺼﺮح ﺑﮫ ﻓﻲ اﻟﺪول اﻷﻋﻀﺎء ﻓﻲ دول اﻻﺗﺤﺎد اﻷوروﺑﻲ ﺑﺎﻟﻤﺴﻤﯿﺎت اﻵﺗﯿﺔ:</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right"><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="margin-left:124.7pt; margin-right:124.0pt; text-align:right"><strong>اﺳﻢ اﻟﻤﺴﺘﺤﻀﺮ</strong></p></td><td style="border-color:black; height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-left:45.7pt; margin-right:44.9pt; text-align:right"><strong>اﻟﺪوﻟﺔ</strong></p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس 1 %</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.6pt; text-align:right">ﺑﻠﺠﯿﻜﺎ</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل 1 % 10) ﻣﻠﺠﻢ / 1 ﻣﻠﻲ ﻟﺘﺮ( ﻓﺮﯾﺰﻧﯿﻮس ﻣﺴﺘﺤﻠﺐ ﻟﻠﺤﻘﻦ أو اﻟﻀﺦ</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">اﻟﻤﺎﻧﯿﺎ</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل 1 % ﻓﺮﯾﺰﻧﯿﻮس</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="text-align:right">اﻟﯿﻮﻧﺎن</p></td></tr><tr><td style="border-color:black; height:13.85pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس 10 ﻣﻠﺠﻢ / ﻣﻠﻲ ﻟﺘﺮ ﻣﺴﺘﺤﻠﺐ ﻟﻠﺤﻘﻦ أو اﻟﻀﺦ</p></td><td style="height:13.85pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">ﻓﺮﻧﺴﺎ</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="margin-right:4.75pt; text-align:right">ﻓﺮﯾﺰﻧﯿﻮس ﺑﺮوﺑﻮﻓﻮل 1 %</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">اﯾﺮﻻﻧﺪا</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل 1 % ﻓﺮﯾﺰﻧﯿﻮس</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">اﻟﺒﺮﺗﻐﺎل</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس 10 ﻣﻠﺠﻢ / ﻣﻠﻲ ﻟﺘﺮ ﻣﺴﺘﺤﻠﺐ ﻟﻠﺤﻘﻦ أو اﻟﻀﺦ</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">اﺳﺒﺎﻧﯿﺎ</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="text-align:right">ﺑﺮوﺑﻮﻓﻮل ﻓﺮﯾﺰﻧﯿﻮس ﻛﺎﺑﻰ 10 ﻣﻠﺠﻢ / ﻣﻠﻲ ﻟﺘﺮ</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">اﻟﺴﻮﯾﺪ</p></td></tr><tr><td style="border-color:black; height:13.75pt; vertical-align:top; width:460px"><p dir="RTL" style="margin-right:4.75pt; text-align:right">ﻓﺮﯾﺰﻧﯿﻮس ﺑﺮوﺑﻮﻓﻮل 1 %</p></td><td style="height:13.75pt; vertical-align:top; width:107px"><p dir="RTL" style="margin-right:4.7pt; text-align:right">اﻟﻤﻤﻠﻜﺔ اﻟﻤﺘﺤﺪة</p></td></tr></tbody></table><p dir="RTL" style="margin-left:0cm; margin-right:22.75pt; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ﻣﺎرس 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol 1 % (10 mg/1 ml) Fresenius emulsion for injection or infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml emulsion contains 10 mg propofol.
Each 20 ml ampoule contains 200 mg propofol.
Each 50 ml vial contains 500 mg propofol.
Each 100 ml vial contains 1000 mg propofol.
Excipients with known effect:
1 ml emulsion contains:
soya-bean oil, refined 100 mg
sodium max. 0.06 mg
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emulsion for injection or infusion.
White oil-in-water emulsion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol 1% is a short-acting intravenous general anaesthetic for:<br />Induction and maintenance of general anaesthesia in adults and children &gt;1 month.<br />Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children &gt;1 month.<br />Sedation of ventilated patients &gt;16 years of age in the intensive care unit.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For specific guidance relating to the administration of Propofol 1% with a target controlled infusion (TCI) device, which incorporates Diprifusor&#39; TCI Software, see Section 4.2.5. Such use is restricted to induction and maintenance of anaesthesia in adults. The &#39;Diprifusor&#39; TCI system is not recommended for use in ICU sedation or sedation for surgical and diagnostic procedures, or in children.<br />4.2.1 Induction of General Anaesthesia Adults<br />In unpremedicated and premedicated patients, it is recommended that Propofol 1% should be titrated (approximately 4 ml [40 mg] every 10 seconds in an average healthy adult by bolus injection or infusion) against the response of the patient until the clinical signs show the onset of anaesthesia. Most adult patients aged less than 55 years are likely to require 1.5-2.5 mg/kg of Propofol 1%. The total dose required can be reduced by lower rates of administration (2-5 ml/min [20-50 mg/min]). Over this age, the requirement will generally be less. In patients of ASA Grades 3 and 4, lower rates of administration should be used (approximately 2 ml [20 mg] every 10 seconds).<br />Older people<br />In older people the dose requirement for induction of anaesthesia with Propofol 1% is reduced. The reduction should<br />take into account of the physical status and age of the patient. The reduced dose should be given at a slower rate and titrated against the response.<br />Paediatric population<br />Propofol 1% is not recommended for induction of anaesthesia in children aged less than 1 month.<br />For induction of anaesthesia in children over 1 month of age, Propofol 1% should be titrated slowly until clinical signs show the onset of anaesthesia. The dose should be adjusted according to age and/or body weight. Most patients over 8 years of age require approximately 2.5 mg/kg body weight of Propofol 1% for induction of anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher (2.5-4 mg/kg body weight).<br />For ASA 3 and 4 patients lower doses are recommended (see also Section 4.4).<br />Administration of Propofol 1% by a &#39;Diprifusor&#39; TCI system is not recommended for induction of general anaesthesia in children.<br />4.2.2 Maintenance of General Anaesthesia Adults<br />Anaesthesia can be maintained by administering Propofol 1% either by continuous infusion or by repeat bolus injections to prevent the clinical signs of light anaesthesia. Recovery from anaesthesia is typically rapid and it is therefore important to maintain Propofol 1% administration until the end of the procedure.<br />Continuous Infusion<br />The required rate of administration varies considerably between patients, but rates in the region of 4-12 mg/kg/h usually maintain satisfactory anaesthesia.<br />Repeat Bolus Injections<br />If a technique involving repeat bolus injections is used, increments of 25 mg (2.5 ml) to 50 mg (5.0 ml) may be given according to clinical need.<br />Older people<br />When Propofol 1% is used for maintenance of anaesthesia the rate of infusion or &#39;target concentration&#39; should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus<br />administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.<br />Paediatric population<br />Propofol 1% is not recommended for maintenance of anaesthesia in children aged less than 1 month.<br />Anaesthesia can be maintained in children over 1 month of age by administering Propofol 1% by infusion or repeated bolus injection to maintain the depth of anaesthesia required. The required rate of administration varies considerably between patients, but rates in the region of 9-15 mg/kg/h usually achieve satisfactory anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher.<br />For ASA 3 and 4 patients lower doses are recommended (see also Section 4.4).<br />Administration of Propofol 1% by a &#39;Diprifusor&#39; TCI system is not recommended for maintenance of general anaesthesia in children.<br />4.2.3 Sedation During Intensive Care Adults<br />For sedation during intensive care it is advised that Propofol 1% should be administered by continuous infusion. The infusion rate should be determined by the desired depth of sedation. In most patients sufficient sedation can be obtained with a dosage of 0.3-4 mg/kg/h of Propofol 1% (See 4.4 Special warnings and precautions for use). Propofol 1% is not indicated for sedation in intensive care of patients of 16 years of age or younger (see 4.3 Contraindications). Administration of Propofol 1% by Diprifusor TCI system is not advised for sedation in the intensive care unit.<br />Propofol 1% may be diluted with 5% Dextrose (see &quot;Dilution and Co-administration&quot; table below).<br />It is recommended that blood lipid levels be monitored should Propofol 1% be administered to patients thought to be at particular risk of fat overload. Administration of Propofol 1% should be adjusted appropriately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the Propofol 1% formulation; 1.0 ml of Propofol 1% contains approximately 0.1g of fat.<br />If the duration of sedation is in excess of 3 days, lipids should be monitored in all patients. Older people<br />When Propofol 1% is used for sedation the rate of infusion should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.<br />Paediatric population<br />Propofol 1% is contraindicated for the sedation of ventilated children aged 16 years or younger receiving intensive care.<br />4.2.4 Sedation For Surgical And Diagnostic Procedures<br />Adults<br />To provide sedation for surgical and diagnostic procedures, rates of administration should be individualised and titrated to clinical response.<br />Most patients will require 0.5-1 mg/kg over 1&mdash; 5 minutes for onset of sedation.<br />Maintenance of sedation may be accomplished by titrating Propofol 1% infusion to the desired level of sedation - most patients will require 1.5-4.5 mg/kg/h. In addition to the infusion, bolus administration of 10-20 mg may be used if a rapid increase in the depth of sedation is required. In patients of ASA Grades 3 and 4 the rate of administration and dosage may need to be reduced.<br />Administration of Propofol 1% by a &#39;Diprifusor&#39; TCI system is not recommended for sedation for surgical and diagnostic procedures.<br />Older people<br />When Propofol 1% is used for sedation the rate of infusion or &#39;target concentration&#39; should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.<br />Paediatric population<br />Propofol 1% is not recommended for surgical and diagnostic procedures in children aged less than 1 month.<br />In children over 1 month of age, doses and administration rates should be adjusted according to the required depth of sedation and the clinical response. Most paediatric patients require 1-2 mg/kg body weight of Propofol 1% for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol 1% infusion to the desired level of sedation. Most patients require 1.5-9 mg/kg/h Propofol 1%. The infusion may be supplemented by bolus administration of up to 1 mg/kg body weight if a rapid increase of depth of sedation is required.<br />In ASA 3 and 4 patients lower doses may be required. 4.2.5 Method of administration<br />Propofol 1% has no analgesic properties and therefore supplementary analgesic agents are generally required in addition to Propofol 1%.<br />Propofol 1% can be used for infusion undiluted from glass containers, plastic syringes or Propofol 1% pre-filled syringes or diluted with 5% Dextrose (Intravenous Infusion BP) only, in PVC infusion bags or glass infusion bottles. Dilutions, which must not exceed 1 in 5 (2 mg propofol per ml) should be prepared aseptically immediately before administration and must be used within 6 hours of preparation.<br />It is recommended that, when using diluted Propofol 1%, the volume of 5% Dextrose removed from the infusion bag during the dilution process is totally replaced in volume by Propofol 1% emulsion. (see &quot;Dilution and Co-administration&quot; table below).<br />The dilution may be used with a variety of infusion control techniques, but a giving set used alone will not avoid the risk of accidental uncontrolled infusion of large volumes of diluted Propofol 1%. A burette, drop counter or volumetric pump must be included in the infusion line. The risk of uncontrolled infusion must be taken into account when deciding the maximum amount of Propofol 1% in the burette.<br />When Propofol 1% is used undiluted to maintain anaesthesia, it is recommended that equipment such as syringe pumps or volumetric infusion pumps should always be used to control infusion rates.<br />Propofol 1% may be administered via a Y-piece close to the injection site into infusions of the following:<br />Dextrose 5% Intravenous Infusion B.P.<br />Sodium Chloride 0.9% Intravenous Infusion B.P.<br />Dextrose 4% with Sodium Chloride 0.18% Intravenous Infusion B.P.<br />The glass pre-filled syringe (PFS) has a lower frictional resistance than plastic disposable syringes and operates more easily. Therefore, if Propofol 1% is administered using a hand held pre-filled syringe, the line between the syringe and the patient must not be left open if unattended.<br />When the pre-filled syringe presentation is used in a syringe pump appropriate compatibility should be ensured. In<br />particular, the pump should be designed to prevent syphoning and should have an occlusion alarm set no greater than 1000 mm Hg. If using a programmable or equivalent pump that offers options for use of different syringes then choose<br />only the &#39;B-D&#39; 50/60 ml &#39;PLASTIP -filled syringe.<br />Propofol 1% may be premixed with alfentanil injection containing 500 micrograms/ml alf I in the ratio of 20:1 to 50:1 v/v. Mixtures should be prepared using sterile technique and used within 6 hours of preparation.<br />In order to reduce pain on initial injection, Propofol 1% may be mixed with preservative-free Lidocaine Injection 0.5% or 1%; (see &quot;Dilution and Co-administration&quot; table below).<br />Target Controlled Infusion - Administration of Propofol 1% by a &#39;Diprifusor&#39; TCI System in Adults<br />Administration of Propofol 1% by a &#39;Diprifusor&#39; TCI system is restricted to induction and maintenance of general anaesthesia in adults. It is not recommended for use in ICU sedation or sedation for surgical and diagnostic procedures, or in children.<br />Propofol 1% may be administered by TCI only with a &#39;Diprifusor&#39; TCI system incorporating &#39;Diprifusor&#39; TCI software. Such systems will operate only on recognition of electronically tagged pre-filled syringes containing Propofol 1% or 2% Injection. The &#39;Diprifusor&#39; TCI system will automatically adjust the infusion rate for the concentration of Propofol<br />recognised. Users must be familiar with the infusion pump users&#39; manual, and with the administration of Propofol 1% by TCI and with the correct use of the syringe identification system.<br />The Diprifusor allows the anaesthetist to achieve and control a desired speed of induction and depth of anaesthesia by setting and adjusting target (predicted) blood concentrations of propofol. An alternative effect-site mode of administration may be accessible on some Diprifusors, but its safety and efficacy have not yet been established.<br />The &#39;Diprifusor&#39; TCI system assumes that the initial blood propofol concentration in the patient is zero. Therefore, in patients who have received prior propofol, there may be a need to select a lower initial target concentration when<br />commencing &#39;Diprifusor&#39; TCI. Similarly, the immediate recommencement of &#39;Diprifusor&#39; TCI is not recommended if the pump has been switched off.<br />Guidance on propofol target concentrations is given below. In view of interpatient variability in propofol pharmacokinetics and pharmacodynamics, in both premedicated and unpremedicated patients the target propofol concentration should be titrated against the response of the patient in order to achieve the depth of anaesthesia required.<br />Induction and Maintenance of General Anaesthesia<br />In adult patients under 55 years of age anaesthesia can usually be induced with target propofol concentrations in the region of 4-8 microgram/ml. An initial target of 4 microgram/ml is recommended in premedicated patients and in unpremedicated patients an initial target of 6 microgram/ml is advised. Induction time with these targets is generally within the range of 60-120 seconds. Higher targets will allow more rapid induction of anaesthesia but may be associated with more pronounced haemodynamic and respiratory depression.<br />A lower initial target concentration should be used in patients over the age of about 55 years and in patients of ASA grades 3 and 4. The target concentration can then be increased in steps of 0.5-1.0 microgram/ml at intervals of 1 minute to achieve a gradual induction of anaesthesia.<br />Supplementary analgesia will generally be required and the extent to which target concentrations for maintenance of anaesthesia can be reduced will be influenced by the amount of concomitant analgesia administered. Target propofol concentrations in the region of 3-6 microgram/ml usually maintain satisfactory anaesthesia.<br />The predicted propofol concentration on waking is generally in the region of 1.0-2.0 microgram/ml and will be influenced by the amount of analgesia given during maintenance.<br />Dilution and Co-Administration of Propofol 1% with Other Drugs or Infusion Fluids (see also &#39;Additional Precautions&#39; Section)<br />&nbsp;</p><table cellspacing="1" cellpadding="1" border="1" style="width:1339px"><tbody><tr><td style="width:211px"><p>Co-administration Technique</p><p>&nbsp;</p></td><td style="width:154px">Additive or Diluent</td><td style="width:742px">Preparation</td><td style="width:231px"><p>Precautions</p><p>&nbsp;</p></td></tr><tr><td style="width:211px">Pre-mixing.</td><td style="width:154px"><p>Dextrose 5% Intravenous Infusion</p><p>&nbsp;</p></td><td style="width:742px"><p>Mix 1 part of Propofol 1% with up to 4 parts of Dextrose 5% Intravenous Infusion B.P in either PVC infusion bags or glass infusion bottles. When diluted in PVC bags it is recommended that the bag should be full and that the dilution be prepared by withdrawing a volume of infusion fluid and replacing it with an equal volume of Propofol i 1%.</p><p>&nbsp;</p></td><td style="width:231px"><p>Prepare aseptically immediately before administration. The mixture is stable for up to 6 hours.</p><p>&nbsp;</p></td></tr><tr><td style="width:211px">&nbsp;</td><td style="width:154px">Lidocaine hydrochloride injection (0.5% or 1% without preservatives)</td><td style="width:742px"><p>Mix 20 parts of Propofol 1% with up to 1 part of either 0.5% or 1% lidocaine hydrochloride injection.</p><p>&nbsp;</p></td><td style="width:231px"><p>Prepare mixture aseptically immediately prior to administration. Use for Induction only.</p><p>&nbsp;</p></td></tr><tr><td style="width:211px">&nbsp;</td><td style="width:154px"><p>Alf I injection (500 microgram/ml).</p><p>&nbsp;</p></td><td style="width:742px"><p>Mix Propofol 1% with alfentanil injection in a ratio of 20:1 to 50:1 v/v.</p><p>&nbsp;</p></td><td style="width:231px"><p>Prepare mixture aseptically; use within 6 hours of preparation.</p><p>&nbsp;</p></td></tr><tr><td style="width:211px">Co-administration via a Y-piece connector</td><td style="width:154px"><p>Dextrose 5% intravenous infusion</p><p>&nbsp;</p></td><td style="width:742px">Co-administer via a Y-piece connector.</td><td style="width:231px"><p>Place the Y-piece connector close to the injection site.</p><p>&nbsp;</p></td></tr><tr><td style="width:211px">&nbsp;</td><td style="width:154px"><p>Sodium chloride 0.9% intravenous infusion</p><p>&nbsp;</p></td><td style="width:742px">As above</td><td style="width:231px">As above</td></tr><tr><td style="width:211px">&nbsp;</td><td style="width:154px"><p>Dextrose 4% with sodium chloride 0.18% intravenous infusion</p><p>&nbsp;</p></td><td style="width:742px">As above</td><td style="width:231px">As above</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Propofol 1% contains soya oil and should not be used in patients who are hypersensitive to peanut or soya.
Propofol 1% must not be used in patients of 16 years of age or younger for sedation in intensive care (see section 4.4). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol 1% should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the care of patients in Intensive Care).<br />Patients should be constantly monitored and facilities for maintenance of a patient airway, artificial ventilation, oxygen enrichment and other resuscitative facilities should be readily available at all times. Propofol 1% should not be<br />administered by the person conducting the diagnostic or surgical procedure.<br />Abuse of, and dependence on Propofol 1%, predominantly by health care professionals, have been reported. As with other general anaesthetics, the administration of Propofol 1% without airway care may result in fatal respiratory complications.<br />When Propofol 1% is administered for conscious sedation, for surgical and diagnostic procedures, patients should be continually monitored for early signs of hypotension, airway obstruction and oxygen desaturation.<br />As with other sedative agents, when Propofol 1% is used for sedation during operative procedures, involuntary patient movements may occur. During procedures requiring immobility these movements may be hazardous to the operative site.<br />An adequate period is needed prior to discharge of the patient to ensure full recovery after use of Propofol 1%. Very rarely the use of Propofol 1% may be associated with the development of a period of postoperative unconsciousness, which may be accompanied by an increase in muscle tone. This may or may not be preceded by a period of wakefulness. Although recovery is spontaneous, appropriate care of an unconscious patient should be administered.<br />Propofol 1% induced impairment is not generally detectable beyond 12 hours. The effects of Propofol 1%, the procedure, concomitant medications, the age and the condition of the patient should be considered when advising patients on:<br />The advisability of being accompanied on leaving the place of administration<br />The timing of recommencement of skilled or hazardous tasks such as driving<br />The use of other agents that may sedate (Eg, benzodiazepines, opiates, alcohol.)<br />As with other intravenous anaesthetic agents, caution should be applied in patients with cardiac, respiratory, renal or hepatic impairment or in hypovolaemic or debilitated patients. Propofol 1% clearance is blood flow dependent, therefore, concomitant medication that reduces cardiac output will also reduce Propofol 1% clearance.<br />Propofol 1% lacks vagolytic activity and has been associated with reports of bradycardia (occasionally profound) and also asystole. The intravenous administration of an anticholinergic agent before induction, or during maintenance of anaesthesia should be considered, especially in situations where vagal tone is likely to predominate, or when Propofol 1% is used in conjunction with other agents likely to cause a bradycardia.<br />As with other intravenous anaesthetic and sedative agents, patients should be instructed to avoid alcohol before and for at least 8 hours after administration of Propofol 1%.<br />During bolus administration for operative procedures, extreme caution should be exercised in patients with acute pulmonary insufficiency or respiratory depression.<br />Concomitant use of central nervous system depressants e.g., alcohol, general anaesthetics, narcotic analgesics will result in accentuation of their sedative effects. When Propofol 1% is combined with centrally depressant drugs administered parenterally, severe respiratory and cardiovascular depression may occur. It is recommended that Propofol 1% is administered following the analgesic and the dose should be carefully titrated to the patient&#39;s response (see Section 4.5).<br />During induction of anaesthesia, hypotension and transient apnoea may occur depending on the dose and use of premedicants and other agents.<br />Occasionally, hypotension may require use of intravenous fluids and reduction of the rate of administration of Propofol 1% during the period of anaesthetic maintenance.<br />When Propofol 1% is administered to an epileptic patient, there may be a risk of convulsion.<br />Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously (see section 4.2).<br />Use is not recommended with electroconvulsive treatment.<br />As with other anaesthetics, sexual disinhibition may occur during recovery.<br />Paediatric population<br />The use of Propofol is not recommended in newborn infants as this patient population has not been fully investigated. Pharmacokinetic data (see section 5.2) indicate that clearance is considerably reduced in neonates and has a very high inter-individual variability. Relative overdose could occur on administering doses recommended for older children and result in severe cardiovascular depression.<br />Propofol 2% is not recommended for use in children &lt; 3 years of age due to difficulty in titrating small volumes.<br />Propofol must not be used in patients of 16 years of age or younger for sedation for intensive care as the safety and<br />efficacy of propofol for sedation in this age group have not been demonstrated (see section 4.3).<br />Advisory statements concerning Intensive Care Unit management<br />Use of propofol emulsion infusions for ICU sedation has been associated with a constellation of metabolic derangements and organ system failures that may result in death. Reports have been received of combinations of the following:<br />Metabolic acidosis, Rhabdomyolysis, Hyperkalaemia, Hepatomegaly, Renal failure, Hyperlipidaemia, Cardiac arrhythmia, Brugada-type ECG (elevated ST-segment and coved T-wave) and rapidly progressive Cardiac failure usually<br />unresponsive to inotropic supportive treatment. Combinations of these events have been referred to as the Propofol<br />Infusion Syndrome. These events were mostly seen in patients with serious head injuries and children with respiratory tract infections who received dosages in excess of those advised in adults for sedation in the intensive care unit.<br />The following appear to be the major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents -vasoconstrictors, steroids, inotropes and/or Propofol 1% (usually at dose rates greater than 4mg/kg/h for more than 48 hours).<br />Prescribers should be alert to these events in patients with the above risk factors and promptly consider decreasing or stopping the Propofol 1% dosage when the above signs develop. All sedative and therapeutic agents used in the<br />intensive care unit (ICU), should be titrated to maintain optimal oxygen delivery and haemodynamic parameters. Patients with raised intra-cranial pressure (ICP) should be given appropriate treatment to support the cerebral perfusion pressure during these treatment modifications.<br />Treating physicians are reminded if possible not to exceed the dosage of 4 mg/kg/h.<br />Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously.<br />It is recommended that blood lipid levels should be monitored if propofol is administered to patients thought to be at particular risk of fat overload. Administration of propofol should be adjusted appropriately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the propofol formulation; 1.0 mL of Propofol contains approximately 0.1 g of fat.<br />Propofol 1% contains 0.0018 mmol sodium per ml. To be taken into consideration by patients on a controlled sodium diet.<br />Additional Precautions<br />Caution should be taken when treating patients with mitochondria! disease. These patients may be susceptible to exacerbations of their disorder when undergoing anaesthesia, surgery and ICU care. Maintenance of normothermia, provision of carbohydrates and good hydration are recommended for such patients. The early presentations of mitochondria! disease exacerbation and of the &#39;propofol infusion syndrome&#39; may be similar.<br />Propofol 1% contains no antimicrobial preservatives and supports growth of micro-organisms.<br />EDTA chelates metal ions, including zinc, and reduces microbial growth rates. The need for supplemental zinc should be considered during prolonged administration of Propofol 1%, particularly in patients who are predisposed to zinc<br />deficiency, such as those with burns, diarrhoea and/or major sepsis.<br />When Propofol 1% is to be aspirated, it must be drawn aseptically into a sterile syringe or giving set immediately after opening the ampoule or breaking the vial seal. Administration must commence without delay. Asepsis must be maintained for both Propofol 1% and infusion equipment throughout the infusion period. Any infusion fluids added to the Propofol 1% line must be administered close to the cannula site. Propofol 1% must not be administered via a microbiological filter.<br />Propofol 1% and any syringe containing Propofol 1% are for single use in an individual patient. In accordance with established guidelines for other lipid emulsions, a single infusion of propofol must not exceed 12 hours. At the end of the procedure or at 12 hours, whichever is the sooner, both the reservoir of propofol and the infusion line must be discarded and replaced as appropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol 1% has been used in association with spinal and epidural anaesthesia and with commonly used premedicants, neuromuscular blocking drugs, inhalational agents and analgesic agents; no pharmacological incompatibility has been encountered. Lower doses of Propofol 1% may be required where general anaesthesia is used as an adjunct to regional anaesthetic techniques. Profound hypertension has been reported following anaesthetic with propofol in patients treated with rifampicin.<br />The concurrent administration of other CNS depressants such as pre-medication drugs, inhalation agents, analgesic agents may add to the sedative, anaesthetic and cardiorespiratory depressant effects of Propofol 1% (see Section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of Propofol 1% during pregnancy has not been established. Propofol 1% should not be given to pregnant women except when absolutely necessary. Propofol 1% can, however, be used during an induced abortion.<br />Obstetrics<br />Propofol 1% crosses the placenta and can cause neonatal depression. It should not be used for obstetric anaesthesia unless clearly necessary.<br />Breast-feeding<br />studies of breastfeeding mothers showed that small quantities of Propofol 1% are excreted in human milk. Women<br />should therefore not breast-feed of Propofol 1%. Milk produced during this period should<br />be discarded.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol 1% has moderate influence on the ability to drive and use machines. Patients should be advised that performance at skilled tasks, such as driving and operating machinery, may be impaired for some time after general anaesthesia.<br />Propofol 1% induced impairment is not generally detectable beyond 12 hours (Section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Induction and maintenance of anaesthesia or sedation is generally smooth with minimal evidence of excitation. The most commonly reported ADRs are pharmacologically predictable side effects of an anaesthetic/sedative agent, such as hypotension. The nature, severity and incidence of adverse events observed in patients receiving Propofol 1% may be related to the condition of the recipients and the operative or therapeutic procedures being undertaken.<br />The following definitions of frequencies are used:<br />Very common (M/10), common (&gt;_1/100 to &lt;1/10), uncommon ((&gt;_1/1,000 to &lt;1/100), rare (M/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).<br />Table of Adverse Drug Reactions</p><p style="margin-left:10.8pt; margin-right:0cm"><strong>Table of Adverse Drug Reactions</strong></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:22.55pt; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm"><strong>System Organ Class</strong></p></td><td style="border-color:black; height:22.55pt; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm"><strong>Frequency</strong></p></td><td style="border-color:black; height:22.55pt; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm"><strong>Undesirable Effects</strong></p></td></tr><tr><td style="border-color:black; height:32.65pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Immune system disorders</p></td><td style="height:32.65pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Very rare</p></td><td style="height:32.65pt; vertical-align:top; width:188.15pt"><p style="margin-left:1.8pt; margin-right:9.0pt">Anaphylaxis &mdash; may include angioedema, bronchospasm, erythema and hypotension</p></td></tr><tr><td style="border-color:black; height:32.15pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Metabolism and nutrition disorders</p></td><td style="height:32.15pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Not known (9)</p></td><td style="height:32.15pt; width:188.15pt"><p style="margin-left:1.8pt; margin-right:10.8pt">Metabolic acidosis (5), hyperkalaemia (5), hyperlipidaemia (5)</p></td></tr><tr><td style="border-color:black; height:32.4pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Psychiatric disorders</p></td><td style="height:32.4pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">T known (9)</p></td><td style="height:32.4pt; width:188.15pt"><p style="margin-left:1.8pt; margin-right:0cm">Euphoric mood. Drug abuse and drug dependence (8)</p></td></tr><tr><td rowspan="4" style="border-color:black; height:27.6pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Nervous system disorders</p></td><td style="height:27.6pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Common</p></td><td style="height:27.6pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Headache during recovery phase</p></td></tr><tr><td style="height:43.45pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Rare</p></td><td style="height:43.45pt; width:188.15pt"><p style="margin-left:1.8pt; margin-right:0cm">Epileptiform movements, including convulsions and opisthotonus during induction, maintenance and recovery</p></td></tr><tr><td style="height:27.1pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Very rare</p></td><td style="height:27.1pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Postoperative unconsciousness</p></td></tr><tr><td style="height:21.6pt; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Not known (9)</p></td><td style="height:21.6pt; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Involuntary movements</p></td></tr><tr><td rowspan="3" style="border-color:black; height:27.15pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Cardiac disorders</p></td><td style="height:27.15pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Common</p></td><td style="height:27.15pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Bradycardia (1)</p></td></tr><tr><td style="height:27.35pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Very rare</p></td><td style="height:27.35pt; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Pulmonary oedema</p></td></tr><tr><td style="height:32.65pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Not known (9)</p></td><td style="height:32.65pt; width:188.15pt"><p style="margin-left:1.8pt; margin-right:10.8pt">Cardiac arrhythmia (5), cardiac failure (5), (<sup>7</sup>)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:27.1pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Vascular disorders</p></td><td style="height:27.1pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Common</p></td><td style="height:27.1pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Hypotension (2)</p></td></tr><tr><td style="height:27.15pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Uncommon</p></td><td style="height:27.15pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Thrombosis and phlebitis</p></td></tr><tr><td rowspan="2" style="border-color:black; height:27.35pt; vertical-align:top; width:174.25pt"><p style="margin-left:1.8pt; margin-right:16.2pt">Respiratory, thoracic and mediastinal disorders</p></td><td style="height:27.35pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Common</p></td><td style="height:27.35pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Transient apnoea during induction</p></td></tr><tr><td style="height:21.6pt; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Not known (9)</p></td><td style="height:21.6pt; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Respiratory depression (dose dependent)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:32.65pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Gastrointestinal disorders</p></td><td style="height:32.65pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Common</p></td><td style="height:32.65pt; width:188.15pt"><p style="margin-left:1.8pt; margin-right:28.8pt">Nausea and vomiting during recovery phase</p></td></tr><tr><td style="height:27.1pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Very rare</p></td><td style="height:27.1pt; vertical-align:top; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Pancreatitis</p></td></tr><tr><td style="border-color:black; height:27.35pt; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Hepatobiliary disorders</p></td><td style="height:27.35pt; vertical-align:top; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Not known (9)</p></td><td style="height:27.35pt; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Hepatomegaly (5)</p></td></tr><tr><td style="height:20.1pt; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Musculoskeletal and connective tissue disorder</p></td><td style="height:20.1pt; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm">Not known (9)</p></td><td style="height:20.1pt; width:188.15pt"><p style="margin-left:2.15pt; margin-right:0cm">Rhabdomyolysis (3), (5)</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:19.1pt; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">&nbsp;</p></td><td style="height:19.1pt; vertical-align:top; width:147.35pt"><p>&nbsp;</p></td><td style="height:19.1pt; width:188.4pt"><p style="margin-left:0cm; margin-right:3.8pt; text-align:right">&nbsp;</p></td></tr><tr><td rowspan="2" style="border-color:black; height:32.65pt; vertical-align:top; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Renal and urinary disorders</p></td><td style="height:32.65pt; vertical-align:top; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Very rare</p></td><td style="height:32.65pt; width:188.4pt"><p style="margin-left:1.8pt; margin-right:7.2pt; text-align:justify">Discolouration of urine following prolonged administration</p></td></tr><tr><td style="height:21.35pt; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Not known (9)</p></td><td style="height:21.35pt; width:188.4pt"><p style="margin-left:2.4pt; margin-right:0cm">Renal failure (5)</p></td></tr><tr><td style="border-color:black; height:32.4pt; width:174.25pt"><p style="margin-left:1.8pt; margin-right:0cm">Reproductive system and breast disorders</p></td><td style="height:32.4pt; vertical-align:top; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Very rare</p></td><td style="height:32.4pt; vertical-align:top; width:188.4pt"><p style="margin-left:2.4pt; margin-right:0cm">Sexual disinhibition</p></td></tr><tr><td rowspan="3" style="border-color:black; height:27.35pt; vertical-align:top; width:174.25pt"><p style="margin-left:1.8pt; margin-right:16.2pt">General disorders and administration site conditions</p></td><td style="height:27.35pt; vertical-align:top; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Very common</p></td><td style="height:27.35pt; vertical-align:top; width:188.4pt"><p style="margin-left:2.4pt; margin-right:0cm">Local pain on induction (4)</p></td></tr><tr><td style="height:32.4pt; vertical-align:top; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Very rare</p></td><td style="height:32.4pt; width:188.4pt"><p style="margin-left:1.8pt; margin-right:18.0pt">Tissue necrosis (10) f !lowing accidental extravascular administration</p></td></tr><tr><td style="height:32.15pt; vertical-align:top; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Not known (9)</p></td><td style="height:32.15pt; width:188.4pt"><p style="margin-left:1.8pt; margin-right:16.2pt">Local pain, swelling, following accidental extravascular administration</p></td></tr><tr><td style="border-color:black; height:21.4pt; width:174.25pt"><p style="margin-left:2.9pt; margin-right:0cm">Investigations</p></td><td style="height:21.4pt; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Not known (9)</p></td><td style="height:21.4pt; width:188.4pt"><p style="margin-left:2.4pt; margin-right:0cm">Brugada type ECG (5), (6)</p></td></tr><tr><td style="border-color:black; height:33.55pt; vertical-align:top; width:174.25pt"><p style="margin-left:1.8pt; margin-right:0cm">Injury, poisoning and procedural complications</p></td><td style="height:33.55pt; vertical-align:top; width:147.35pt"><p style="margin-left:2.4pt; margin-right:0cm">Very rare</p></td><td style="height:33.55pt; vertical-align:top; width:188.4pt"><p style="margin-left:2.4pt; margin-right:0cm">Postoperative fever</p></td></tr></tbody></table><p><br />1) Serious bradycardias are rare. There have been isolated reports of progression to asystole.<br />2) Occasionally, hypotension may require use of intravenous fluids and reduction of the administration rate of Propofol.<br />3) Very rare reports of rhabdomyolysis have been received where Propofol has been given at doses greater than 4 mg/kg/hr for ICU sedation.<br />(4) May be minimised by using the larger veins of the forearm and antecubital fossa. With Propofol 1% local pain can also be minimised by the co-administration of lidocaine.<br />(5) Combinations of these events, reported as &quot;Propofol infusion syndrome&quot;, may be seen in seriously ill patients who often have multiple risk factors for the development of the events, see section 4.4.<br />(6) Brugada-type ECG - elevated ST-segment and coved T-wave in ECG.<br />(7) Rapidly progressive cardiac failure (in some cases with fatal outcome) in adults. The cardiac failure in such cases was usually unresponsive to inotropic supportive treatment.<br />(8) Abuse of and drug dependence on propofol, predominantly by health care professionals.<br />(9) Not known as it cannot be estimated from the available clinical trial data.<br />(10) Necrosis has been reported where tissue viability has been impaired.<br />Dystonia/dyskinesia have been reported.<br />Local<br />The local pain which may occur during the induction phase of Propofol 1% anaesthesia can be minimised by the co-administration of lidocaine (see &quot;Dosage and Administration&quot;) and by the use of the larger veins of the forearm and antecubital fossa. Thrombosis and phlebitis are rare. Accidental clinical extravasation and animal studies showed minimal tissue reaction. Intra-arterial injection in animals did not induce local tissue effects.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Accidental overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by<br />artificial ventilation with oxygen. Cardiovascular depression would require lowering of the patient&#39;s head and, if severe, use of plasma expanders and pressor agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other general anaesthetics<br />ATC code: NO1AX10<br />Mechanism of action<br />Propofol (2, 6-diisopropylphenol) is a short-acting general anaesthetic agent with a rapid onset of action of approximately 30 seconds. Recovery from anaesthesia is usually rapid. The mechanism of action, like all general anaesthetics, is poorly understood. However, propofol is thought to produce its sedative/anaesthetic effects by the positive modulation of the inhibitory function of the neurotransmitter GABA through the ligand-gated GABAA receptors.<br />Pharmacodynamic properties<br />In general, falls in mean arterial blood pressure and slight changes in heart rate are observed when Propofol 1% is administered for induction and maintenance of anaesthesia. However, the haemodynamic parameters normally remain relatively stable during maintenance and the incidence of untoward haemodynamic changes is low.<br />Although ventilatory depression can occur following administration of Propofol 1%, any effects are qualitatively similar to those of other intravenous anaesthetic agents and are readily manageable in clinical practice.<br />Propofol 1% reduces cerebral blood flow, intracranial pressure and cerebral metabolism. The reduction in intracranial pressure is greater in patients with an elevated baseline intracranial pressure.<br />Clinical efficacy and safety<br />Recovery from anaesthesia is usually rapid and clear headed with a low incidence of headache and post-operative nausea and vomiting.<br />In general, there is less post-operative nausea and vomiting following anaesthesia with Propofol 1% than following anaesthesia with inhalational agents. There is evidence that this may be related to a reduced emetic potential of propofol.<br />Propofol 1%, at the concentrations likely to occur clinically, does not inhibit the synthesis of adrenocortical hormones. Paediatric population<br />Limited studies on the duration of propofol based anaesthesia in children indicate safety and efficacy is unchanged up to<br />duration of 4 hours. Literature evidence of use in children documents use for prolonged procedures without changes in safety or efficacy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />When Propofol 1% is used to maintain anaesthesia, blood concentrations asymptotically approach the steady-state value for the given administration rate.<br />Distribution<br />Propofol is extensively distributed and rapidly cleared from the body (total body clearance 1.5-2 litres/minute).<br />Elimination<br />The decline in propofol concentrations following a bolus dose or following the termination of an infusion can be described by a three compartment open model with very rapid distribution (half-life 2 &mdash;4 minutes), rapid elimination (half-life 30 &mdash; 60 minutes), and a slower final phase, representative of redistribution of propofol from poorly perfused tissue.<br />Clearance occurs by metabolic processes, mainly in the liver where it is blood flow dependent, to form inactive conjugates of propofol and its corresponding quinol, which are excreted in urine.<br />After a single dose of 3 mg/kg intravenously, propofol clearance/kg body weight increased with age as follows: Median clearance was considerably lower in neonates &lt;1 month old (n=25) (20 ml/kg/min) compared to older children (n= 36, age range 4 months-7 years). Additionally inter-individual variability was considerable in neonates (range 3.7-78 ml/kg/min). Due to this limited trial data that indicates a large variability, no dose recommendations can be given for this age group.<br />Median propofol clearance in older aged children after a single 3 mg/kg bolus was 37.5 ml/min/kg (4-24 months) (n=8), 38.7 ml/min/kg (11-43 months) (n=6), 48 ml/min/kg (1-3 years)(n=12), 28.2 ml/min/kg (4-7 years)(n=10) as compared with 23.6 ml/min/kg in adults (n=6).<br />Linearity<br />The pharmacokinetics are linear over the recommended range of infusion rates of Propofol 1%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol is a drug on which extensive clinical experience has been obtained. All relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol Ph Eur<br />Purified Egg Phosphatide<br />Sodium Hydroxide Ph Eur<br />Soya-bean Oil, Refined Ph Eur Water for Injections Ph Eur Nitrogen Ph Eur<br />Disodium Edetate Ph Eur</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The neuromuscular blocking agents, atracurium and mivacurium should not be given through the same intravenous line as Propofol 1% without prior flushing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3.1 Shelf life of the product as packaged for sale
Ampoules 3 years
Vials 3 years
6.3.2 Shelf life after dilution
Use of diluted Propofol must begin immediately following dilution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25 &deg;C. Do not freeze.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless glass ampoule(s) (type I) of 20 ml<br />Colourless glass vial(s) (type II) of 50 ml with a bromobutyl rubber closure<br />Colourless glass vial(s) (type II) of 100 ml with a bromobutyl rubber closure<br />Packs containing 5 glass ampoules with 20 ml emulsion<br />Packs containing 10 glass ampoules with 20 ml emulsion<br />Packs containing 1 glass vial with 50 or 100 ml emulsion<br />Packs containing 10 glass vials with 50 or 100 ml emulsion<br />Packs containing 15 glass vials with 50 or 100 ml emulsion<br />Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In-use precautions<br />Containers should be shaken before use.<br />Any portion of the contents remaining after use should be discarded.<br />Propofol 1% should not be mixed prior to administration with injections or infusion fluids other than 5% Dextrose or Lidocaine Injection (see Section 4.2.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Deutschland GmbH

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                31/01/2017

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>